MXPA99007626A - 7a-HETEROCYCLE-SUBSTITUTED HEXAHYDRO-1H-PYRROLIZINE COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION - Google Patents
7a-HETEROCYCLE-SUBSTITUTED HEXAHYDRO-1H-PYRROLIZINE COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSIONInfo
- Publication number
- MXPA99007626A MXPA99007626A MXPA/A/1999/007626A MX9907626A MXPA99007626A MX PA99007626 A MXPA99007626 A MX PA99007626A MX 9907626 A MX9907626 A MX 9907626A MX PA99007626 A MXPA99007626 A MX PA99007626A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrrolizine
- hexahydro
- carbon atoms
- pyridinyl
- alkyl
- Prior art date
Links
- 230000005062 synaptic transmission Effects 0.000 title claims abstract description 27
- 230000001276 controlling effect Effects 0.000 title claims description 8
- 239000000126 substance Substances 0.000 title description 22
- ADRDEXBBJTUCND-UHFFFAOYSA-N Pyrrolizidine Chemical class C1CCN2CCCC21 ADRDEXBBJTUCND-UHFFFAOYSA-N 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 149
- -1 7a-Substituted hexahydro-1H-pyrrolizine compounds Chemical class 0.000 claims abstract description 107
- 239000000203 mixture Substances 0.000 claims abstract description 79
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 241000124008 Mammalia Species 0.000 claims abstract description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 5
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 80
- 125000000217 alkyl group Chemical group 0.000 claims description 38
- 239000011780 sodium chloride Substances 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 30
- 125000003545 alkoxy group Chemical group 0.000 claims description 28
- 125000003282 alkyl amino group Chemical group 0.000 claims description 13
- 108020003175 receptors Proteins 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 125000001188 haloalkyl group Chemical group 0.000 claims description 11
- 230000027455 binding Effects 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 125000004429 atoms Chemical group 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 8
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 6
- 229940002612 prodrugs Drugs 0.000 claims description 6
- 235000010290 biphenyl Nutrition 0.000 claims description 5
- 239000004305 biphenyl Substances 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 5
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- 125000001041 indolyl group Chemical group 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 5
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 5
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 5
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 5
- 125000000335 thiazolyl group Chemical group 0.000 claims description 5
- 125000001544 thienyl group Chemical group 0.000 claims description 5
- IUEQEOCBANZKNS-UHFFFAOYSA-N 3-(1,2,3,5,6,7-hexahydropyrrolizin-8-yl)quinoline Chemical compound C1=CC=CC2=CC(C34CCCN3CCC4)=CN=C21 IUEQEOCBANZKNS-UHFFFAOYSA-N 0.000 claims description 4
- HZJLPAMWNPUMAU-UHFFFAOYSA-N 5-(1,2,3,5,6,7-hexahydropyrrolizin-8-yl)-3-methyl-1,2-oxazole Chemical compound O1N=C(C)C=C1C1(CCC2)N2CCC1 HZJLPAMWNPUMAU-UHFFFAOYSA-N 0.000 claims description 4
- HPOZGOWFPFFGGF-UHFFFAOYSA-N 8-(2,6-difluoropyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine Chemical compound FC1=NC(F)=CC=C1C1(CCC2)N2CCC1 HPOZGOWFPFFGGF-UHFFFAOYSA-N 0.000 claims description 4
- FBCZOUTZSBKDFZ-UHFFFAOYSA-N 8-(2-chloropyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine Chemical compound ClC1=NC=CC=C1C1(CCC2)N2CCC1 FBCZOUTZSBKDFZ-UHFFFAOYSA-N 0.000 claims description 4
- PFZGGTLHFZSUOM-UHFFFAOYSA-N 8-(5-bromo-6-fluoropyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine Chemical compound C1=C(Br)C(F)=NC=C1C1(CCC2)N2CCC1 PFZGGTLHFZSUOM-UHFFFAOYSA-N 0.000 claims description 4
- MDNQNAXYVRIBIT-UHFFFAOYSA-N 8-(6-chloro-5-methylpyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine Chemical compound N1=C(Cl)C(C)=CC(C23N(CCC2)CCC3)=C1 MDNQNAXYVRIBIT-UHFFFAOYSA-N 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- DCRZRVUQVMFHES-UHFFFAOYSA-N 3-benzyl-5-(1,2,3,5,6,7-hexahydropyrrolizin-8-yl)-1,2-oxazole Chemical compound C1=C(C23N(CCC2)CCC3)ON=C1CC1=CC=CC=C1 DCRZRVUQVMFHES-UHFFFAOYSA-N 0.000 claims description 3
- GYGWBEASOHKHOU-UHFFFAOYSA-N 5-(1,2,3,5,6,7-hexahydropyrrolizin-8-yl)-3-propyl-1,2-oxazole Chemical compound O1N=C(CCC)C=C1C1(CCC2)N2CCC1 GYGWBEASOHKHOU-UHFFFAOYSA-N 0.000 claims description 3
- UOVDDNKPWGIYET-UHFFFAOYSA-N 5-(1,2,3,5,6,7-hexahydropyrrolizin-8-yl)pyridin-3-ol Chemical compound OC1=CN=CC(C23N(CCC2)CCC3)=C1 UOVDDNKPWGIYET-UHFFFAOYSA-N 0.000 claims description 3
- IVBCYXSJGHULGX-UHFFFAOYSA-N 8-(2,6-dichloropyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine Chemical compound ClC1=NC(Cl)=CC=C1C1(CCC2)N2CCC1 IVBCYXSJGHULGX-UHFFFAOYSA-N 0.000 claims description 3
- DFFMJYFFJSEMBW-UHFFFAOYSA-N 8-(2-fluoropyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine Chemical compound FC1=NC=CC=C1C1(CCC2)N2CCC1 DFFMJYFFJSEMBW-UHFFFAOYSA-N 0.000 claims description 3
- GBULOOWMAALEIV-UHFFFAOYSA-N 8-(4-methylpyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine Chemical compound CC1=CC=NC=C1C1(CCC2)N2CCC1 GBULOOWMAALEIV-UHFFFAOYSA-N 0.000 claims description 3
- GAVOQWNHINFWNX-UHFFFAOYSA-N 8-(5,6-dichloropyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine Chemical compound N1=C(Cl)C(Cl)=CC(C23N(CCC2)CCC3)=C1 GAVOQWNHINFWNX-UHFFFAOYSA-N 0.000 claims description 3
- LZYMEEIXSXDUIM-UHFFFAOYSA-N 8-(5-bromopyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine Chemical compound BrC1=CN=CC(C23N(CCC2)CCC3)=C1 LZYMEEIXSXDUIM-UHFFFAOYSA-N 0.000 claims description 3
- LJHVQQOANJYPPO-UHFFFAOYSA-N 8-(5-chloro-6-fluoropyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine Chemical compound C1=C(Cl)C(F)=NC=C1C1(CCC2)N2CCC1 LJHVQQOANJYPPO-UHFFFAOYSA-N 0.000 claims description 3
- OYBCNMWNCANIMQ-UHFFFAOYSA-N 8-(5-phenylmethoxypyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine Chemical compound C=1N=CC(C23N(CCC2)CCC3)=CC=1OCC1=CC=CC=C1 OYBCNMWNCANIMQ-UHFFFAOYSA-N 0.000 claims description 3
- GZPGNTLETMYSDN-UHFFFAOYSA-N 8-(5-phenylpyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine Chemical compound C1CCN2CCCC21C(C=1)=CN=CC=1C1=CC=CC=C1 GZPGNTLETMYSDN-UHFFFAOYSA-N 0.000 claims description 3
- TYKKWQQDPZUUHU-UHFFFAOYSA-N 8-(6-chloropyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine Chemical compound C1=NC(Cl)=CC=C1C1(CCC2)N2CCC1 TYKKWQQDPZUUHU-UHFFFAOYSA-N 0.000 claims description 3
- ZKJJWXCWZLJXQX-UHFFFAOYSA-N 8-(6-fluoro-5-methylpyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine Chemical compound N1=C(F)C(C)=CC(C23N(CCC2)CCC3)=C1 ZKJJWXCWZLJXQX-UHFFFAOYSA-N 0.000 claims description 3
- OUZPAHMAMKESPP-UHFFFAOYSA-N 8-(6-fluoropyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine Chemical compound C1=NC(F)=CC=C1C1(CCC2)N2CCC1 OUZPAHMAMKESPP-UHFFFAOYSA-N 0.000 claims description 3
- KVRHWOQPVGAXNB-UHFFFAOYSA-N 8-(6-methylpyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine Chemical compound C1=NC(C)=CC=C1C1(CCC2)N2CCC1 KVRHWOQPVGAXNB-UHFFFAOYSA-N 0.000 claims description 3
- QKLTTXBWHTWIKI-UHFFFAOYSA-N 8-pyridin-3-yl-1,2,3,5,6,7-hexahydropyrrolizine Chemical compound C1CCN2CCCC21C1=CC=CN=C1 QKLTTXBWHTWIKI-UHFFFAOYSA-N 0.000 claims description 3
- JWWWWAAWTMNKCE-UHFFFAOYSA-N 8-pyrimidin-5-yl-1,2,3,5,6,7-hexahydropyrrolizine Chemical compound C1CCN2CCCC21C1=CN=CN=C1 JWWWWAAWTMNKCE-UHFFFAOYSA-N 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 125000005418 aryl aryl group Chemical group 0.000 claims description 2
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims description 2
- 108010052671 nicotinic receptor alpha4beta2 Proteins 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 110
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 86
- 239000000243 solution Substances 0.000 description 82
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 78
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 70
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 66
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 65
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 64
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 62
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 57
- 239000007787 solid Substances 0.000 description 57
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 51
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 50
- 238000003756 stirring Methods 0.000 description 49
- 239000000741 silica gel Substances 0.000 description 47
- 229910002027 silica gel Inorganic materials 0.000 description 47
- 239000002904 solvent Substances 0.000 description 45
- 239000011541 reaction mixture Substances 0.000 description 43
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 38
- 238000004587 chromatography analysis Methods 0.000 description 37
- 238000006243 chemical reaction Methods 0.000 description 36
- 239000003921 oil Substances 0.000 description 36
- 235000019198 oils Nutrition 0.000 description 36
- 235000019439 ethyl acetate Nutrition 0.000 description 31
- 239000008079 hexane Substances 0.000 description 29
- 239000012071 phase Substances 0.000 description 26
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 24
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 24
- 235000019341 magnesium sulphate Nutrition 0.000 description 24
- OFBQJSOFQDEBGM-UHFFFAOYSA-N pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 24
- 239000008346 aqueous phase Substances 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 20
- 239000000843 powder Substances 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 210000004027 cells Anatomy 0.000 description 18
- 239000002858 neurotransmitter agent Substances 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 17
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 16
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 16
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 16
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- SJOPDOYYINOFEH-UHFFFAOYSA-M 1,2,3,5,6,7-hexahydropyrrolizin-4-ium;perchlorate Chemical compound [O-]Cl(=O)(=O)=O.C1CCC2=[N+]1CCC2 SJOPDOYYINOFEH-UHFFFAOYSA-M 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 14
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 14
- 229940079593 drugs Drugs 0.000 description 12
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 11
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 229920001223 polyethylene glycol Polymers 0.000 description 11
- 230000001242 postsynaptic Effects 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 10
- UAOMVDZJSHZZME-UHFFFAOYSA-N Diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-ZSJDYOACSA-N water-d2 Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 10
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000001537 neural Effects 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 229910052763 palladium Inorganic materials 0.000 description 9
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 8
- SNICXCGAKADSCV-JTQLQIEISA-N Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 8
- 229960002715 Nicotine Drugs 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 229960003638 dopamine Drugs 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 239000006187 pill Substances 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 239000007909 solid dosage form Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 102000014415 Muscarinic acetylcholine receptor family Human genes 0.000 description 7
- 108050003473 Muscarinic acetylcholine receptor family Proteins 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 229920002892 amber Polymers 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 239000006196 drop Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 125000001072 heteroaryl group Chemical group 0.000 description 7
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 230000003000 nontoxic Effects 0.000 description 7
- 231100000252 nontoxic Toxicity 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- 239000001993 wax Substances 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- VLTRZXGMWDSKGL-UHFFFAOYSA-M Perchlorate Chemical compound [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 6
- AKHNMLFCWUSKQB-UHFFFAOYSA-L Sodium thiosulphate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 6
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 6
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- LKYXEULZVGJVTG-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH] LKYXEULZVGJVTG-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- KZMGYPLQYOPHEL-UHFFFAOYSA-N ethoxyethane;trifluoroborane Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 6
- 239000003701 inert diluent Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 235000019345 sodium thiosulphate Nutrition 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 6
- ODGCEQLVLXJUCC-UHFFFAOYSA-N tetrafluoroborate Chemical compound F[B-](F)(F)F ODGCEQLVLXJUCC-UHFFFAOYSA-N 0.000 description 6
- 206010001497 Agitation Diseases 0.000 description 5
- 210000003169 Central Nervous System Anatomy 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 235000010443 alginic acid Nutrition 0.000 description 5
- 229920000615 alginic acid Chemical class 0.000 description 5
- 238000006555 catalytic reaction Methods 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000008297 liquid dosage form Substances 0.000 description 5
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminum hydride Chemical compound [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229930015196 nicotine Natural products 0.000 description 5
- 230000002335 preservative Effects 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 235000012239 silicon dioxide Nutrition 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000008247 solid mixture Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 230000001225 therapeutic Effects 0.000 description 5
- 239000000080 wetting agent Substances 0.000 description 5
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-Bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 4
- 229960004373 Acetylcholine Drugs 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 4
- WTEOIRVLGSZEPR-UHFFFAOYSA-N Boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- DGTNSSLYPYDJGL-UHFFFAOYSA-N Phenylisocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 4
- 229960004063 Propylene glycol Drugs 0.000 description 4
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 235000010419 agar Nutrition 0.000 description 4
- 235000012216 bentonite Nutrition 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 239000006172 buffering agent Substances 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 230000003111 delayed Effects 0.000 description 4
- 229940043279 diisopropylamine Drugs 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 230000001404 mediated Effects 0.000 description 4
- 230000000051 modifying Effects 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000003518 presynaptic Effects 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- SOSPMXMEOFGPIM-UHFFFAOYSA-N 3,5-dibromopyridine Chemical compound BrC1=CN=CC(Br)=C1 SOSPMXMEOFGPIM-UHFFFAOYSA-N 0.000 description 3
- KNQBCZCROOZYAZ-UHFFFAOYSA-N 8-(5-methylpyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine Chemical compound CC1=CN=CC(C23N(CCC2)CCC3)=C1 KNQBCZCROOZYAZ-UHFFFAOYSA-N 0.000 description 3
- PVWJVTHJDXHNNB-UHFFFAOYSA-N 8-ethynyl-1,2,3,5,6,7-hexahydropyrrolizine Chemical compound C1CCN2CCCC21C#C PVWJVTHJDXHNNB-UHFFFAOYSA-N 0.000 description 3
- PXAJQJMDEXJWFB-UHFFFAOYSA-N Acetone oxime Chemical compound CC(C)=NO PXAJQJMDEXJWFB-UHFFFAOYSA-N 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 210000004556 Brain Anatomy 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 241000206672 Gelidium Species 0.000 description 3
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010061536 Parkinson's disease Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 229940116362 Tragacanth Drugs 0.000 description 3
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000034433 acetylcholine receptors Human genes 0.000 description 3
- 108020000715 acetylcholine receptors Proteins 0.000 description 3
- 150000001345 alkine derivatives Chemical group 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- 235000019445 benzyl alcohol Nutrition 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 230000001713 cholinergic Effects 0.000 description 3
- 229940110456 cocoa butter Drugs 0.000 description 3
- 235000019868 cocoa butter Nutrition 0.000 description 3
- 235000012343 cottonseed oil Nutrition 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000006193 diazotization reaction Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 230000002708 enhancing Effects 0.000 description 3
- 239000002702 enteric coating Substances 0.000 description 3
- 125000004185 ester group Chemical group 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000005842 heteroatoms Chemical group 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000000968 intestinal Effects 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 210000002569 neurons Anatomy 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 230000001681 protective Effects 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 3
- 239000001187 sodium carbonate Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000000946 synaptic Effects 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissues Anatomy 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- SJKJUPFXBZEWHH-UHFFFAOYSA-N 1-O-benzyl 2-O-methyl 2-(3-hydroxypropyl)pyrrolidine-1,2-dicarboxylate Chemical compound OCCCC1(C(=O)OC)CCCN1C(=O)OCC1=CC=CC=C1 SJKJUPFXBZEWHH-UHFFFAOYSA-N 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- ODLHBFYUZBAWAD-UHFFFAOYSA-N 5-(1,2,3,5,6,7-hexahydropyrrolizin-8-yl)pyridin-3-ol;hydrochloride Chemical compound Cl.OC1=CN=CC(C23N(CCC2)CCC3)=C1 ODLHBFYUZBAWAD-UHFFFAOYSA-N 0.000 description 2
- YTHMOBMZVVFNBE-UHFFFAOYSA-N 6-fluoropyridin-3-amine Chemical compound NC1=CC=C(F)N=C1 YTHMOBMZVVFNBE-UHFFFAOYSA-N 0.000 description 2
- MWUPKEXFJWEPSR-UHFFFAOYSA-N 8-(2,6-difluoropyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine;hydrochloride Chemical compound Cl.FC1=NC(F)=CC=C1C1(CCC2)N2CCC1 MWUPKEXFJWEPSR-UHFFFAOYSA-N 0.000 description 2
- BRSIRBORBXAYGZ-UHFFFAOYSA-N 8-(5-chloro-6-fluoropyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine;hydrochloride Chemical compound Cl.C1=C(Cl)C(F)=NC=C1C1(CCC2)N2CCC1 BRSIRBORBXAYGZ-UHFFFAOYSA-N 0.000 description 2
- LVYUCHHRQAVPBQ-UHFFFAOYSA-N 8-(5-methylpyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine;hydrochloride Chemical compound Cl.CC1=CN=CC(C23N(CCC2)CCC3)=C1 LVYUCHHRQAVPBQ-UHFFFAOYSA-N 0.000 description 2
- MCZYBFPKTRLGRZ-UHFFFAOYSA-N 8-(6-fluoro-5-methylpyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine;hydrochloride Chemical compound Cl.N1=C(F)C(C)=CC(C23N(CCC2)CCC3)=C1 MCZYBFPKTRLGRZ-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 2
- BHELZAPQIKSEDF-UHFFFAOYSA-N Allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 2
- HJJPJSXJAXAIPN-UHFFFAOYSA-N Arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 2
- 206010003736 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N Benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 229960003563 Calcium Carbonate Drugs 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N Carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 102000009660 Cholinergic Receptors Human genes 0.000 description 2
- 108010009685 Cholinergic Receptors Proteins 0.000 description 2
- 241000744472 Cinna Species 0.000 description 2
- DERZBLKQOCDDDZ-UHFFFAOYSA-N Cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1CC=CC1=CC=CC=C1 DERZBLKQOCDDDZ-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- UXDSSCRWRAACCH-UHFFFAOYSA-N ON=C(C)CC=O Chemical compound ON=C(C)CC=O UXDSSCRWRAACCH-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 210000003463 Organelles Anatomy 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N Perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 229940067631 Phospholipids Drugs 0.000 description 2
- 210000000664 Rectum Anatomy 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 210000002182 Synaptic Membranes Anatomy 0.000 description 2
- 108060008443 TPPP Proteins 0.000 description 2
- BSYVTEYKTMYBMK-UHFFFAOYSA-N Tetrahydro-2-furanmethanol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 241000209149 Zea Species 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical class [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000003655 absorption accelerator Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 229940027983 antiseptics and disinfectants Quaternary ammonium compounds Drugs 0.000 description 2
- 201000006287 attention deficit hyperactivity disease Diseases 0.000 description 2
- 230000002567 autonomic Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229960004217 benzyl alcohol Drugs 0.000 description 2
- 229960002903 benzyl benzoate Drugs 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 229910000090 borane Inorganic materials 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbamate Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N cdcl3 Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 235000005824 corn Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000002999 depolarising Effects 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- CQDGTJPVBWZJAZ-UHFFFAOYSA-M ethyl carbonate Chemical compound CCOC([O-])=O CQDGTJPVBWZJAZ-UHFFFAOYSA-M 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 239000003885 eye ointment Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 238000011068 load Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- LROBJRRFCPYLIT-UHFFFAOYSA-M magnesium;ethyne;bromide Chemical compound [Mg+2].[Br-].[C-]#C LROBJRRFCPYLIT-UHFFFAOYSA-M 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N n-methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical class [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 150000002828 nitro derivatives Chemical class 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 150000002829 nitrogen Chemical group 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Chemical class 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 201000006040 primary spontaneous pneumothorax Diseases 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical class CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 239000003340 retarding agent Substances 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 150000004760 silicates Chemical class 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 230000000392 somatic Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical class CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000003206 sterilizing agent Substances 0.000 description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 description 2
- 125000004426 substituted alkynyl group Chemical group 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical class [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000000699 topical Effects 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- 239000011778 trisodium citrate Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- PIPAJLPNWZMYQA-UHFFFAOYSA-N (8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate Chemical compound C[N+]1(C)C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 PIPAJLPNWZMYQA-UHFFFAOYSA-N 0.000 description 1
- GXFZCDMWGMFGFL-KKXMJGKMSA-N +)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 1
- OSUKITADBQXORD-UHFFFAOYSA-N 1,2,3,5,6,7-hexahydropyrrolizin-4-ium Chemical compound C1CCC2=[N+]1CCC2 OSUKITADBQXORD-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical group C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- BLQYEDXWEDWCNJ-LBPRGKRZSA-N 1-O-benzyl 2-O-methyl (2S)-pyrrolidine-1,2-dicarboxylate Chemical compound COC(=O)[C@@H]1CCCN1C(=O)OCC1=CC=CC=C1 BLQYEDXWEDWCNJ-LBPRGKRZSA-N 0.000 description 1
- MNUBHPMBKWLXMN-UHFFFAOYSA-N 1-O-benzyl 2-O-methyl 2-(3-methylsulfonyloxypropyl)pyrrolidine-1,2-dicarboxylate Chemical compound CS(=O)(=O)OCCCC1(C(=O)OC)CCCN1C(=O)OCC1=CC=CC=C1 MNUBHPMBKWLXMN-UHFFFAOYSA-N 0.000 description 1
- VEGJZLTZKPJEFI-UHFFFAOYSA-N 1-O-benzyl 2-O-methyl 2-prop-2-enylpyrrolidine-1,2-dicarboxylate Chemical compound COC(=O)C1(CC=C)CCCN1C(=O)OCC1=CC=CC=C1 VEGJZLTZKPJEFI-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- NALZTFARIYUCBY-UHFFFAOYSA-N 1-nitrobutane Chemical compound CCCC[N+]([O-])=O NALZTFARIYUCBY-UHFFFAOYSA-N 0.000 description 1
- JSZOAYXJRCEYSX-UHFFFAOYSA-N 1-nitropropane Chemical compound CCC[N+]([O-])=O JSZOAYXJRCEYSX-UHFFFAOYSA-N 0.000 description 1
- XSHFSZAXOOQKQS-UHFFFAOYSA-N 2,3-dichloro-5-iodopyridine Chemical compound ClC1=CC(I)=CN=C1Cl XSHFSZAXOOQKQS-UHFFFAOYSA-N 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- FILKGCRCWDMBKA-UHFFFAOYSA-N 2,6-dichloropyridine Chemical compound ClC1=CC=CC(Cl)=N1 FILKGCRCWDMBKA-UHFFFAOYSA-N 0.000 description 1
- MBTGBRYMJKYYOE-UHFFFAOYSA-N 2,6-difluoropyridine Chemical compound FC1=CC=CC(F)=N1 MBTGBRYMJKYYOE-UHFFFAOYSA-N 0.000 description 1
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-Chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 1
- POPPVIRYGJQIOF-UHFFFAOYSA-N 2-acetyloxyethyl(trimethyl)azanium;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound CC(=O)OCC[N+](C)(C)C.CN1CCCC1C1=CC=CN=C1 POPPVIRYGJQIOF-UHFFFAOYSA-N 0.000 description 1
- VPJXQGSRWJZDOB-UHFFFAOYSA-O 2-carbamoyloxyethyl(trimethyl)azanium Chemical compound C[N+](C)(C)CCOC(N)=O VPJXQGSRWJZDOB-UHFFFAOYSA-O 0.000 description 1
- UGNNEHISWQTVJM-UHFFFAOYSA-N 2-chloro-4-methyl-3-nitropyridine;4-methylpyridin-3-amine Chemical compound CC1=CC=NC=C1N.CC1=CC=NC(Cl)=C1[N+]([O-])=O UGNNEHISWQTVJM-UHFFFAOYSA-N 0.000 description 1
- RKRUYZVVYJIPRA-UHFFFAOYSA-N 2-chloro-5-iodo-3-methylpyridine Chemical compound CC1=CC(I)=CN=C1Cl RKRUYZVVYJIPRA-UHFFFAOYSA-N 0.000 description 1
- XFRGDECOCIZNGF-UHFFFAOYSA-N 2-chloro-5-iodo-3-methylpyridine;6-chloro-5-methylpyridin-3-amine Chemical compound CC1=CC(N)=CN=C1Cl.CC1=CC(I)=CN=C1Cl XFRGDECOCIZNGF-UHFFFAOYSA-N 0.000 description 1
- QWLGCWXSNYKKDO-UHFFFAOYSA-N 2-chloro-5-iodopyridine Chemical compound ClC1=CC=C(I)C=N1 QWLGCWXSNYKKDO-UHFFFAOYSA-N 0.000 description 1
- PWUMXWNORXBMJH-UHFFFAOYSA-N 2-chloro-5-nitropyridine;2-fluoro-5-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(F)N=C1.[O-][N+](=O)C1=CC=C(Cl)N=C1 PWUMXWNORXBMJH-UHFFFAOYSA-N 0.000 description 1
- RVHOBHMAPRVOLO-UHFFFAOYSA-L 2-ethylbutanedioate Chemical class CCC(C([O-])=O)CC([O-])=O RVHOBHMAPRVOLO-UHFFFAOYSA-L 0.000 description 1
- CFKHKTLGKNBEPI-UHFFFAOYSA-N 2-fluoro-3-methyl-5-nitropyridine Chemical compound CC1=CC([N+]([O-])=O)=CN=C1F CFKHKTLGKNBEPI-UHFFFAOYSA-N 0.000 description 1
- INXPRWIQPCLWQD-UHFFFAOYSA-N 2-fluoro-5-iodo-3-methylpyridine Chemical compound CC1=CC(I)=CN=C1F INXPRWIQPCLWQD-UHFFFAOYSA-N 0.000 description 1
- FWGJDRWJVFYBSG-UHFFFAOYSA-N 2-fluoro-5-iodo-3-methylpyridine;6-fluoro-5-methylpyridin-3-amine Chemical compound CC1=CC(N)=CN=C1F.CC1=CC(I)=CN=C1F FWGJDRWJVFYBSG-UHFFFAOYSA-N 0.000 description 1
- XOZAJNLUAODXSP-UHFFFAOYSA-N 2-fluoro-5-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(F)N=C1 XOZAJNLUAODXSP-UHFFFAOYSA-N 0.000 description 1
- MTAODLNXWYIKSO-UHFFFAOYSA-N 2-fluoropyridine Chemical compound FC1=CC=CC=N1 MTAODLNXWYIKSO-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- USZINSZJSVMICC-UHFFFAOYSA-N 2-methyl-5-nitropyridine Chemical compound CC1=CC=C([N+]([O-])=O)C=N1 USZINSZJSVMICC-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- XAWCLWKTUKMCMO-UHFFFAOYSA-N 2-nitroethylbenzene Chemical compound [O-][N+](=O)CCC1=CC=CC=C1 XAWCLWKTUKMCMO-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical class [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- JTHZLMIOTSBCFB-UHFFFAOYSA-N 3-(1,2,3,5,6,7-hexahydropyrrolizin-8-yl)quinoline;dihydrochloride Chemical compound Cl.Cl.C1=CC=CC2=CC(C34CCCN3CCC4)=CN=C21 JTHZLMIOTSBCFB-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- AYWRUZTUCAGENI-UHFFFAOYSA-N 3-benzyl-5-(1,2,3,5,6,7-hexahydropyrrolizin-8-yl)-1,2-oxazole;hydrochloride Chemical compound Cl.C1=C(C23N(CCC2)CCC3)ON=C1CC1=CC=CC=C1 AYWRUZTUCAGENI-UHFFFAOYSA-N 0.000 description 1
- YSHKYZAWTWKQKK-UHFFFAOYSA-N 3-bromo-5-phenylmethoxypyridine Chemical compound BrC1=CN=CC(OCC=2C=CC=CC=2)=C1 YSHKYZAWTWKQKK-UHFFFAOYSA-N 0.000 description 1
- NYPYPOZNGOXYSU-UHFFFAOYSA-N 3-bromopyridine Chemical compound BrC1=CC=CN=C1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 1
- ZGIKWINFUGEQEO-UHFFFAOYSA-N 3-bromoquinoline Chemical compound C1=CC=CC2=CC(Br)=CN=C21 ZGIKWINFUGEQEO-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-M 3-cyclopentylpropanoate Chemical class [O-]C(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-M 0.000 description 1
- DKWGDURXHCRIKW-UHFFFAOYSA-N 3-ethyl-5-(1,2,3,5,6,7-hexahydropyrrolizin-8-yl)-1,2-oxazole Chemical compound O1N=C(CC)C=C1C1(CCC2)N2CCC1 DKWGDURXHCRIKW-UHFFFAOYSA-N 0.000 description 1
- SMXBHXFTAWZFAU-UHFFFAOYSA-N 3-iodo-4-methylpyridine Chemical compound CC1=CC=NC=C1I SMXBHXFTAWZFAU-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical class [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- IBKMZYWDWWIWEL-UHFFFAOYSA-N 4-methylpyridin-3-amine Chemical compound CC1=CC=NC=C1N IBKMZYWDWWIWEL-UHFFFAOYSA-N 0.000 description 1
- KHPVEVHQQRDRMO-UHFFFAOYSA-N 5-(1,2,3,5,6,7-hexahydropyrrolizin-8-yl)-3-methyl-1,2-oxazole;hydrochloride Chemical compound Cl.O1N=C(C)C=C1C1(CCC2)N2CCC1 KHPVEVHQQRDRMO-UHFFFAOYSA-N 0.000 description 1
- YVOJSBCMODDUIK-UHFFFAOYSA-N 5-(1,2,3,5,6,7-hexahydropyrrolizin-8-yl)-3-propyl-1,2-oxazole;hydrochloride Chemical compound Cl.O1N=C(CCC)C=C1C1(CCC2)N2CCC1 YVOJSBCMODDUIK-UHFFFAOYSA-N 0.000 description 1
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 1
- GYCPLYCTMDTEPU-UHFFFAOYSA-N 5-bromopyrimidine Chemical compound BrC1=CN=CN=C1 GYCPLYCTMDTEPU-UHFFFAOYSA-N 0.000 description 1
- KADQKKYTJHXBSL-UHFFFAOYSA-N 6-fluoro-5-methylpyridin-3-amine Chemical compound CC1=CC(N)=CN=C1F KADQKKYTJHXBSL-UHFFFAOYSA-N 0.000 description 1
- UENBBJXGCWILBM-UHFFFAOYSA-N 6-methylpyridin-3-amine Chemical compound CC1=CC=C(N)C=N1 UENBBJXGCWILBM-UHFFFAOYSA-N 0.000 description 1
- HVWLEGOXGIRRFD-UHFFFAOYSA-N 8-(2,6-dichloropyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine;hydrochloride Chemical compound Cl.ClC1=NC(Cl)=CC=C1C1(CCC2)N2CCC1 HVWLEGOXGIRRFD-UHFFFAOYSA-N 0.000 description 1
- VDSQBTBYZPSYRR-UHFFFAOYSA-N 8-(2-chloropyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine;hydrochloride Chemical compound Cl.ClC1=NC=CC=C1C1(CCC2)N2CCC1 VDSQBTBYZPSYRR-UHFFFAOYSA-N 0.000 description 1
- BTUHVYVDCMKPSN-UHFFFAOYSA-N 8-(2-fluoropyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine;hydrochloride Chemical compound Cl.FC1=NC=CC=C1C1(CCC2)N2CCC1 BTUHVYVDCMKPSN-UHFFFAOYSA-N 0.000 description 1
- PEEOHDPSTARMSP-UHFFFAOYSA-N 8-(4-methylpyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine;dihydrochloride Chemical compound Cl.Cl.CC1=CC=NC=C1C1(CCC2)N2CCC1 PEEOHDPSTARMSP-UHFFFAOYSA-N 0.000 description 1
- FQCXZBQTCLSVPA-UHFFFAOYSA-N 8-(4-methylpyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine;hydrochloride Chemical compound Cl.CC1=CC=NC=C1C1(CCC2)N2CCC1 FQCXZBQTCLSVPA-UHFFFAOYSA-N 0.000 description 1
- JGRBYXAURQXYQW-UHFFFAOYSA-N 8-(5,6-dichloropyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine;hydrochloride Chemical compound Cl.N1=C(Cl)C(Cl)=CC(C23N(CCC2)CCC3)=C1 JGRBYXAURQXYQW-UHFFFAOYSA-N 0.000 description 1
- WUBIDTJPKGKCQD-UHFFFAOYSA-N 8-(5-bromo-6-fluoropyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine;hydrochloride Chemical compound Cl.C1=C(Br)C(F)=NC=C1C1(CCC2)N2CCC1 WUBIDTJPKGKCQD-UHFFFAOYSA-N 0.000 description 1
- UVNGJNIQKVNWGX-UHFFFAOYSA-N 8-(5-bromopyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine;hydrochloride Chemical compound Cl.BrC1=CN=CC(C23N(CCC2)CCC3)=C1 UVNGJNIQKVNWGX-UHFFFAOYSA-N 0.000 description 1
- LFQIJZQNKNSAIZ-UHFFFAOYSA-N 8-(5-fluoropyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine Chemical compound FC1=CN=CC(C23N(CCC2)CCC3)=C1 LFQIJZQNKNSAIZ-UHFFFAOYSA-N 0.000 description 1
- DDRMNTMIQJAHSD-UHFFFAOYSA-N 8-(5-phenylpyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine;hydrochloride Chemical compound Cl.C1CCN2CCCC21C(C=1)=CN=CC=1C1=CC=CC=C1 DDRMNTMIQJAHSD-UHFFFAOYSA-N 0.000 description 1
- AEKAAQMNMQSAIH-UHFFFAOYSA-N 8-(6-chloro-5-methylpyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine;hydrochloride Chemical compound Cl.N1=C(Cl)C(C)=CC(C23N(CCC2)CCC3)=C1 AEKAAQMNMQSAIH-UHFFFAOYSA-N 0.000 description 1
- IKKYWNSZDGLNHU-UHFFFAOYSA-N 8-(6-chloropyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine;hydrochloride Chemical compound Cl.C1=NC(Cl)=CC=C1C1(CCC2)N2CCC1 IKKYWNSZDGLNHU-UHFFFAOYSA-N 0.000 description 1
- UJYFNYAMAJNDTF-UHFFFAOYSA-N 8-(6-fluoropyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine;hydrochloride Chemical compound Cl.C1=NC(F)=CC=C1C1(CCC2)N2CCC1 UJYFNYAMAJNDTF-UHFFFAOYSA-N 0.000 description 1
- XBKVOGXFXYPPCO-UHFFFAOYSA-N 8-(6-methylpyridin-3-yl)-1,2,3,5,6,7-hexahydropyrrolizine;dihydrochloride Chemical compound Cl.Cl.C1=NC(C)=CC=C1C1(CCC2)N2CCC1 XBKVOGXFXYPPCO-UHFFFAOYSA-N 0.000 description 1
- PYLODWICBLPASA-UHFFFAOYSA-N 8-pyridin-3-yl-1,2,3,5,6,7-hexahydropyrrolizine;hydrochloride Chemical compound Cl.C1CCN2CCCC21C1=CC=CN=C1 PYLODWICBLPASA-UHFFFAOYSA-N 0.000 description 1
- SQNHRVVFCKRHPL-UHFFFAOYSA-N 8-pyrimidin-5-yl-1,2,3,5,6,7-hexahydropyrrolizine;hydrochloride Chemical compound Cl.C1CCN2CCCC21C1=CN=CN=C1 SQNHRVVFCKRHPL-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 240000005781 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 229940072107 Ascorbate Drugs 0.000 description 1
- 229940009098 Aspartate Drugs 0.000 description 1
- 210000003050 Axons Anatomy 0.000 description 1
- 229940050390 Benzoate Drugs 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- WPKQGCZVJGYMFU-UHFFFAOYSA-N C1(=CC=CC=C1)C=C[N+](=O)[O-].C1(=CC=CC=C1)CC[N+](=O)[O-] Chemical compound C1(=CC=CC=C1)C=C[N+](=O)[O-].C1(=CC=CC=C1)CC[N+](=O)[O-] WPKQGCZVJGYMFU-UHFFFAOYSA-N 0.000 description 1
- 229960004484 CARBACHOL Drugs 0.000 description 1
- 229960005069 Calcium Drugs 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Carbodicyclohexylimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229920002301 Cellulose acetate Polymers 0.000 description 1
- 229960004926 Chlorobutanol Drugs 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 241001111317 Chondrodendron tomentosum Species 0.000 description 1
- MTBYHRNVNFKEEK-UHFFFAOYSA-N ClC1=NC=C(C=C1C)[N+](=O)[O-].FC1=NC=C(C=C1C)[N+](=O)[O-] Chemical compound ClC1=NC=C(C=C1C)[N+](=O)[O-].FC1=NC=C(C=C1C)[N+](=O)[O-] MTBYHRNVNFKEEK-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 239000008709 Curare Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical class OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 229940047652 Ear Drops Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 230000036826 Excretion Effects 0.000 description 1
- 210000002683 Foot Anatomy 0.000 description 1
- 108091006011 G proteins Proteins 0.000 description 1
- 102000030007 GTP-Binding Proteins Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins Proteins 0.000 description 1
- 210000004907 Glands Anatomy 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N Glycerol 3-phosphate Chemical class OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229940015042 Glycopyrrolate Drugs 0.000 description 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 1
- 238000007341 Heck reaction Methods 0.000 description 1
- VHHHONWQHHHLTI-UHFFFAOYSA-N Hexachloroethane Chemical compound ClC(Cl)(Cl)C(Cl)(Cl)Cl VHHHONWQHHHLTI-UHFFFAOYSA-N 0.000 description 1
- 206010021113 Hypothermia Diseases 0.000 description 1
- 210000003405 Ileum Anatomy 0.000 description 1
- 229940102223 Injectable Solution Drugs 0.000 description 1
- 229940102213 Injectable Suspension Drugs 0.000 description 1
- 229960000367 Inositol Drugs 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 210000001503 Joints Anatomy 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical class OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 229940001447 Lactate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N Lactobionic acid Chemical class OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L Magnesium hydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 210000001259 Mesencephalon Anatomy 0.000 description 1
- 206010027646 Miosis Diseases 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 229940097496 Nasal Spray Drugs 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N Nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 229940049964 Oleate Drugs 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 229940041678 Oral Spray Drugs 0.000 description 1
- 230000035536 Oral bioavailability Effects 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical class C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 210000001428 Peripheral Nervous System Anatomy 0.000 description 1
- HXITXNWTGFUOAU-UHFFFAOYSA-N Phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 1
- 229950010765 Pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical class CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 102000004659 Presynaptic Receptors Human genes 0.000 description 1
- 108010003717 Presynaptic Receptors Proteins 0.000 description 1
- 206010061920 Psychotic disease Diseases 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N Pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000000528 Ricinus communis Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 240000003670 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 240000001016 Solanum tuberosum Species 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical class OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 1
- 229940032712 Succinylcholine Drugs 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 210000000225 Synapses Anatomy 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical class [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000005466 alkylenyl group Chemical group 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001078 anti-cholinergic Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Chemical class 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 229940095076 benzaldehyde Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical class [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N borate Chemical class [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229920005557 bromobutyl Polymers 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical class CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-M camphorsulfonate anion Chemical class C1CC2(CS([O-])(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M caproate Chemical class CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- 239000000064 cholinergic agonist Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 230000001149 cognitive Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002860 competitive Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- DMJZZSLVPSMWCS-UHFFFAOYSA-N diborane Chemical compound B1[H]B[H]1 DMJZZSLVPSMWCS-UHFFFAOYSA-N 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- PQMWYJDJHJQZDE-UHFFFAOYSA-M diethyl-methyl-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium;bromide Chemical group [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-M dodecyl sulfate Chemical class CCCCCCCCCCCCOS([O-])(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-M 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical class CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000036749 excitatory postsynaptic potential Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229960002462 glycopyrronium bromide Drugs 0.000 description 1
- 101710004774 gua1 Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical class CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- LMYQAZODCDGPSE-UHFFFAOYSA-N hexa-1,2,3,4-tetraene Chemical group [CH2+][C]=C=C=C=C LMYQAZODCDGPSE-UHFFFAOYSA-N 0.000 description 1
- 239000002035 hexane extract Substances 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical class OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 230000002631 hypothermal Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000036734 inhibitory postsynaptic potential Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-M isethionate Chemical class OCCS([O-])(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-M 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M isothiocyanate Chemical class [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical class CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M laurate Chemical class CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- OCZDCIYGECBNKL-UHFFFAOYSA-N lithium;alumanuide Chemical compound [Li+].[AlH4-] OCZDCIYGECBNKL-UHFFFAOYSA-N 0.000 description 1
- 231100000875 loss of motor control Toxicity 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical class [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical class [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical class CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical class [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- XOBKSJJDNFUZPF-UHFFFAOYSA-N methoxyethyl Chemical group CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 101700074809 mpaF Proteins 0.000 description 1
- 210000000663 muscle cells Anatomy 0.000 description 1
- 125000001298 n-hexoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N n-methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical class C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000000842 neuromuscular blocking agent Substances 0.000 description 1
- 230000000324 neuroprotective Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical class CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 230000036220 oral bioavailability Effects 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atoms Chemical group O* 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M palmitate Chemical class CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical class [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 230000036231 pharmacokinetics Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- ZFGVGZZHOSHPEN-UHFFFAOYSA-N phenyl(quinolin-3-yl)diazene Chemical class C1=CC=CC=C1N=NC1=CN=C(C=CC=C2)C2=C1 ZFGVGZZHOSHPEN-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical class [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000011528 polyamide (building material) Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L propanedioate Chemical class [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000002633 protecting Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical group 0.000 description 1
- 229910052904 quartz Inorganic materials 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000979 retarding Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000002048 spasmolytic Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical class [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- AXOIZCJOOAYSMI-UHFFFAOYSA-N succinylcholine Chemical compound C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C AXOIZCJOOAYSMI-UHFFFAOYSA-N 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229960001531 suxamethonium Drugs 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- BRKFQVAOMSWFDU-UHFFFAOYSA-M tetraphenylphosphanium;bromide Chemical compound [Br-].C1=CC=CC=C1[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 BRKFQVAOMSWFDU-UHFFFAOYSA-M 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical class CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-M undecanoate Chemical class CCCCCCCCCCC([O-])=O ZDPHROOEEOARMN-UHFFFAOYSA-M 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical class CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Abstract
7a-Substituted hexahydro-1H-pyrrolizine compounds having formula (I), wherein A is a defined heterocycle moiety, pharmaceutical compositions of these compounds, and use of said compositions to selectively control synaptic transmission in mammals.
Description
Hexahydro-1 H-pyrrolizine 7a-heterocycle-substituted compounds useful for controlling chemical synaptic transmission
TECHNICAL FIELD This invention relates to exahydro-1 H-pyrrolizine 7a-heterocycle-substituted compounds, which control chemical synaptic transmission; to therapeutically effective pharmaceutical compositions of these compounds; and to the use of said compositions to control synaptic transmission in mammals.
BACKGROUND OF THE INVENTION Compounds that selectively control chemical synaptic transmission offer therapeutic utility for treating disorders that are associated with dysfunctions in synaptic transmission. This utility may arise from controlling either pre-synaptic or post-synaptic chemical transmission. The control of the synaptic chemical transmission is, in turn, a direct result of a modulation of the excitability of the synaptic membrane. The presynaptic control of membrane excitability results from the direct effect that an active compound has on the organelles and enzymes present in the nerve terminal to synthesize, store and release the neurotransmitter, as well as the process for re-uptake. The post-synaptic control of membrane excitability results from the influence that an active compound has on the cytoplasmic organelles that respond to the neurotransmitter action.
An explanation of the processes involved in chemical synaptic transmission will help to illustrate more fully the potential applications of the invention. (For a more complete explanation of the chemical synaptic transmission refer to Hoffman et al., "Neurotransmission: The autonomic and somatic motor nervous systems" (Neurotransmission: autonomic and somatic motor nervous systems) In: Goodman and Gilman's, The Pharmacoloqical Basis of Therapeutics, 9th ed., JG Hardman, LE Limbird, PB Molinoff, RW Ruddon, and A. Goodman Gilman, eds., Pergamon Press, New York, 1996, pp. 1 05-139). Normally, chemical synaptic transmission begins with a stimulus that depolarizes the transmembrane potential of the synaptic junction above the threshold that produces an all-or-nothing action potential in a nerve axon. The action potential propagates to the terminal nerve, where the ion fluxes activate a mobilization process that leads to the secretion of neurotransmitters and the "transmission" to the post-synaptic cell. Those cells, which receive communication from the central and peripheral nervous systems in the form of neurotransmitters, are referred to as "excitable cells". Excitable cells are cells such as nerves, soft muscle cells, cardiac cells and glands. The effect of a neurotransmitter on an excitable cell may be to cause either an excitatory or inhibitory post-synaptic potential (EPSP or I PSP, respectively) depending on the nature of the post-synaptic receptor for the particular neurotransmitter and the degree to which, other neurotransmitters are present. Whether a particular neurotransmitter causes excitation or inhibition depends mainly on the ion channels that open up in the post-synaptic membrane (ie, in the excitable cell). EPSPs usually result from a local depolarization of the membrane due to the increased permeability generalized to cations (notably Na + and K +), while I PSPs are the result of stabilization or hyperpolarization of membrane excitability due to an increase in permeability for mostly smaller ions (including K + and CI ") For example, acetylcholine neurotransmitter excites skeletal muscle joints by opening permeability channels for Na + and K + At other synapses, such as cardiac cells, acetylcholine can be inhibitory , resulting mainly from an increase in K + conductance.The biological effects of the compounds of the present invention result from the modulation of a particular subtype of acetylcholine receptor., it is important to understand the differences between two receptor subtypes. The two distinct subfamilies of acetylcholine receptors are defined as nicotinic acetylcholine receptors and muscarinic acetylcholine receptors. (See Goodman and Gilman's, The Pharmacological Basis of Therapeutics, op. Cit.). The responses of these receptor subtypes are mediated by two completely different classes of second messenger systems. When the nicotinic aceticoline receptor is activated, the response is an increased flow of specific extracellular ions (eg, Na +, K + and Ca "" ") through the neuronal membrane.In contrast, muscarinic acetylcholine receptor activation leads In this way, the biological consequences of nicotinic acetylcholine receptor activation are different from those of the muscarinic receptor activation, in an analogous manner to intracellular systems, which contain complex molecules, such as G proteins and inositol phosphates. , the inhibition of nicotinic acetylcholine receptors results in still other biological effects, which are different and different from those that arise from inhibition of muscarinic receptor.As indicated above, the two main sites to which the drug compounds that affect the chemical synaptic transmission can be directed, they are the nerve terminal pre-sin optics and the postsynaptic membrane. The actions of drugs directed to the pre-synaptic site can be mediated through presynaptic receptors that respond to the neurotransmitter, which has released the same secretory structure (that is, through a self-receptor), or through a pre-receptor. synaptic that responds to another neurotransmitter (that is, through a hetero-receptor). The actions of drugs directed to the post-synaptic membrane imitate the action of the endogenous neurotransmitter or inhibit the interaction of the endogenous neurotransmitter with a post-synaptic receptor. Classical examples of drugs that modulate post-synaptic membrane excitability are neuromuscular blocking agents, which interact with nicotinic acetylcholine gate channel receptors in skeletal muscle, for example, competitive agents (stabilizers), such as, curare, or depolarizing agents, such as, succinylcholine.
In the central nervous system, post-synaptic cells may have many neurotransmitters that make an effect on them. This makes it difficult to know the precise net balance of the chemical synaptic transmission required to control a given cell. However, when designing compounds that selectively affect only one pre- or post-synaptic receiver, it is possible to modulate the net balance of all other inputs. Obviously, the more one understands about chemical synaptic transmission in CNS disorders, the easier it will be to design drugs to treat such disorders. Knowing how specific neurotransmitters act in the
CNS allows one to speculate on disorders that may be treatable with certain CNS-active drugs. For example, dopamine is widely recognized as an important neurotransmitter in the central nervous system in humans and animals. Many aspects of the pharmacology of dopamine have been reviewed by Roth and Elsworth, "Biochemical Pharmacology of Midbrain Dopamine Neurons" (Biochemical Pharmacology of Neurons of the Brain Center of Dopamine), In: Psvchopharmacology: The Fourth Generation of Proqress, FE Bloom and DJ Kupfer, Eds, Raven Press, NY, 1995, pp 227-243). Patients with Parkinson's disease have a primary loss of neurons containing dopamine from the nigrostriatal route, which results in profound loss of motor control. It has been found that therapeutic strategies to replace dopamine deficiency with dopamine mimics, as well as administering pharmacological agents that modify the release of dopamine and other neurotransmitters have a therapeutic benefit ("Parkinson's Disease", in:
Psychopharmacoloav: The Fourth Generation of Progress, op. cit. , pp 1479-1484). Other studies have shown that certain compounds, which potently affect neurotransmission in nicotinic acetylcholine receptors, are effective for pain relief (Badio et al., Drug Devel. Res., 1995, 36: 46-59). Neuroprotective actions have also been found for several nicotinic acetylcholine receptor ligands, as reviewed in Brioni et al. , Med. Chem. Res., 1 996, 487-51 0. Still selective and new neurotransmitter controlling agents are being seen, in the hope that one or more will be useful in important but still poorly controlled disease states or models of behavior. For example, dementia, as seen with Alzheimer's or Parkinson's disease, remains highly untreatable. The symptoms of chronic alcoholism and nicotine withdrawal involve aspects of the central nervous system, as does Attention Deficit Disorder (ADD) behavior disorder. Specific agents for treatment of these and related disorders are few or nonexistent. A more complete discussion of the possible utility as agents
CNS-active compounds with activity as selective cholinergic ligands for neuronal nicotinic receptors, (i.e., to control chemical synaptic transmission) can be found in U.S. Patent 5,472,958 to Gunn et al. , issued December 5, 1995, which is incorporated herein by reference. Existing acetylcholine agonists are therapeutically sub-optimal to treat the conditions discussed above. For example, such compounds have unfavorable pharmacokinetics (e.g., arecoline and nicotine), poor potency and lack of selectivity (e.g., nicotine), poor CNS penetration (e.g., carbachol) or poor oral bioavailability (e.g., nicotine) . In addition, other agents have many undesired central agonist actions, including hypothermia, hipolocomodation and tremor, and peripheral side effects, including miosis, lacrimation, defecation, and tachycardia (Benowitz et al., In: Nicotine Psychopharmacology, S. Wonnacott, MAH Russell, & I. P. Stolerman, eds. , Oxford University Press, Oxford, 1990, p. 12-157; and M. Davidson, et al. , in Current Research in Alzheimer Therapy, E. Giacobini and R. Becker, ed.; Taylor & Francis: New York, 1988; pp 333-336). Orlek et al (PCT application WO 91/1 3885, published September 19, 1991) describe bridged azabicyclic compounds that support triazine substituents having utility for enhancing acetylcholine function via action on muscarinic receptors in the central nervous system . Hedley et al (European Patent Application 287,356, published October 19, 1988) describe bridged azabicyclic compounds that support 5-membered heteroaromatic ring substituents, having utility for enhancing acetylcholine function via the action on muscarinic receptors in the nervous system central.
Baker et al. (European patent application 412,798, published February 1, 1 991) disclose pyrazine, pyridazine and pyrimidine compounds substituted with various azabicyclic ring portions having utility for stimulating the central muscarinic acetylcholine receptors. Carmosin et al. (U.S. Patent 4,800,207, issued January 24, 1989) disclose hexahydropyrrolizines substituted with various hetero ring containing portions having utility in pharmaceutical compositions for treating pain. Carmosin et al. (U.S. Patent 4,582,836, issued April 5, 1986) describe octahydroindolizidines substituted with various hetero ring containing portions, which have utility in pharmaceutical compositions for treating pain. Miyana et al. (European patent application 39, 903, published November 1, 1981) describe pyrrolizidines substituted in position 8 with acyclic substituents having spasmolytic activity in the soft muscle of guinea pig ileum.
BRIEF DESCRIPTION OF THE INVENTION It has been found, in accordance with the present invention, that certain hexahydro-1H-pyrrolizine 7a-heterocycle-substituted compounds are selective and potent cholinergic compounds useful for selectively controlling synaptic transmission. In its main aspect, the present invention provides a compound of formula (I) below, or a pharmaceutically acceptable salt thereof, wherein a 7a-hexahydro-1 H-pyrrolizine is directly linked to a 5-isoxazole group, -pyrazol, 3-pyridine, 5-pyrimidine, 2-pyrazine, 3-pyridazine, or substituted 3-quinoline. Another aspect of the present invention provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (I), in combination with a pharmaceutically acceptable carrier or diluent. In still another aspect, the present invention provides a method for selectively controlling synaptic transmission in a mammal. A further aspect of the invention is a process for preparing compounds of formula (I). The novel compounds of the present invention are represented by the formula (I):
or a pharmaceutically acceptable salt or prodrug thereof, wherein the group designated A is selected from the group consisting of:
wherein R1 is C ^ Cs-alkyl, as defined below, -CH2-aryl, -CH2-substituted aryl, or -CH2-CH2-substituted aryl, wherein aryl and substituted-aryl are as defined below;
wherein R.1 is as defined above, and R2 is H or d -Cs-alkyl;
wherein R3 is substituted at the 2, 4 or 6 position and is selected from the group consisting of H, C? -C3-alkyl, Br, Cl or F; and R 4 is substituted in one of the remaining positions not occupied by R 3 and is independently selected from the group consisting of H, dCa-alkyl, Br, Cl, F or dCs-alkyl-O-; or when substituted at position 5, R4 may be further selected from the group consisting of (1) O-R6, wherein R6 is selected from the group consisting of;
(a) hydrogen, (b) alkyl of one to six carbon atoms, (c) alkenium of one to six carbon atoms, (d) alkynyl of one to six carbon atoms, (e) haloalkyl of one to six atoms carbon, (f) hydroxyalkyl of two to six carbon atoms, (h) amino, (i) alkylamino of one to six carbon atoms, (j) dialkylamino, in which the two alkyl groups are independently from one to six carbon atoms, (k) phenyl, (I) naphthyl, (m) biphenyl, (n) furyl, (o) thienyl, (p) pyridinyl, (q) pyrazinyl, (r) pyridazinyl, (s) pyrimidinyl, t) pyrrolyl, (u) pyrazolyl, (v) imidazolyl, (w) indolyl, (x) thiazolyl, (and) oxazolyl, (z) isozasolyl, (aa) thiadiazolyl, (bb) oxadiazolyl, (ce) quinolinyl, ( dd) isoquinolinyl, (ee) aryl-C? -C6-alkyl, (ff) heteroaryl-C? -C6-alkyl t (gg) any of groups (i) to (ff) of R6 above substituted in the aromatic ring with one or two substituents independently selected from the group consisting of alkyl of one to six carbon atoms, haloalkyl of one to six carbon atoms, alkoxy of one to six carbon atoms, alkoxyalkyl, in which the alkoxy and alkyl portions are independently from one to six carbon atoms, alkoxyalkoxy, in which the alkoxy portions are independently of one to six carbon atoms, halogen, cyano, hydroxy, amino, alkylamino of one to six carbon atoms, carboxyl and alkoxycarbonyl of two to six carbon atoms; (2) -S-R6, wherein R6 is as defined above; (3) -N (R6) (R7), wherein R6 is as defined above and R7 is selected from H or alkyl of 1 to 6 carbon atoms; (4) LR8, wherein L is absent or selected from the group consisting of (a) - (CH2) P-, where p is 1 to 6; (b) - (CH = CH) q-, where q is one or two; (c) -C (O) -; (d) -OC (O) -; (e) -N (R7) -C (O) -, wherein R7 is as defined above; (f) -CH2-CH2-C (O) -; (g) -CH2-O-C (O) -; -CH2-N H-C (O) -; or (h) -C = C-; and wherein -R8 is selected from the group consisting of: (a) hydrogen; (b) alkyl of one to six carbon atoms, (c) alkenyl of one to six carbon atoms, (d) alkynyl of one to six carbon atoms, (e) haloalkyl of one to six carbon atoms, (f) ) hydroxyalkyl of two to six carbon atoms,
(g) alkoxy of one to six carbon atoms (h) amino, (i) alkylamino of one to six carbon atoms, (j) dialkylamino, in which the two alkyl groups are independently from one to six carbon atoms,
(k) phenyl, (I) naphthyl, (m) biphenyl, (n) furyl, (o) thienyl, (p) pyridinyl, (q) pyrazinyl, (r) pyridazinyl, (s) pyrimidinyl, (t) pyrrolyl, (u) pyrazolyl, (v) imidazolyl, (w) indolyl, (x) thiazolyl, (y) oxazolyl, (z) isozasolyl, (aa) thiadiazolyl, (bb) oxadiazolyl, (ce) quinolinyl, (dd) isoquinolinyl, and (ee) any of the groups (i) to (dd) of R 6 above substituted with one or two substituents independently selected from the group consisting of alkyl of one to six carbon atoms, haloalkyl of one to six carbons, alkoxy from one to six carbon atoms, alkoxyalkyl, in which the alkoxy and alkyl portions are independently from one to six carbon atoms, alkoxyalkoxy, in which the alkoxy portions are independently from one to six carbon atoms, halogen, cyano, hydroxy, amino, alkylamino of one to six carbon atoms, carboxyl, and alkoxycarbonyl of two to six carbon atoms; with the requirement that in groups of the type -O-R6, -S-R6, -N (R6) (R7) and L-R8, none of R6, -N (R6) (R7) or L-R8 can contain a nitrogen atom, which is conjugated with a double or triple ligature;
(d) where R3 is as defined above;
(e), where R3 is as defined above;
(f) where R3 is as defined above; and (g) wherein R5 is H, d-Cs-alkyl, Cl or F.
DETAILED DESCRIPTION OF THE INVENTION Certain compounds of this invention may possess one or more asymmetric centers and may exist in optically active forms. Additional asymmetric centers may be present in a substituent group, such as an alkyl group. The compounds of the invention, which have one or more asymmetric carbon atoms, may exist as the optically pure enantiomers, pure diastereomers, mixtures of enantiomers, mixtures of diastereomers, racemic mixtures of enantiomers, diastereomeric racemates or mixtures of diastereomeric racemates. It should be understood that the present invention anticipates and includes within its scope all those isomers and mixtures thereof. The terms "R" and "S" used herein are configurations as defined in 1 UPAC 1 974 Recommendations for Section E, Fundamental Stereochemistry, Puré Appl. Chem., 1976, 45: 13-30. In particular, the stereochemistry at position 7a and the point of attachment of A, as shown in Formula (I), can be independently either (R) or (S), unless specifically noted otherwise. The chiral forms of certain compounds of this invention are contemplated and are specifically included within the scope of this invention.
"Alkoxy" refers to an alkyl group, as previously defined, attached to the parent molecular moiety through an oxygen atom.
Examples of alkoxy of one to six carbon atoms include, but are not limited to, methoxy, ethoxy, propoxy, iso-propoxy, n-butoxy, tert-butoxy, neo-pentoxy and n-hexoxy. The term "alkoxyalkoxy" refers to an alkoxy group, as defined above, substituted by the replacement of a hydrogen atom of the alkyl portion thereof with an alkoxy group. Examples of alkoxyalkoxy include, but are not limited to methoxymethoxy, methoxyethoxy, ethoxyethoxy, methoxypropoxy, and the like. The term "alkoxyalkyl" refers to an alkyl group, as defined above, substituted with one or more alkoxy groups. Examples of alkoxyalkyl include methoxymethyl, methoxyethyl, hydroxypropyl, methoxypropyl and the like. The term "alkoxycarbonyl" refers to an alkoxy group, as defined above, connected to the parent molecular moiety through a carbonyl linking group. Examples of alkoxycarbonyl include methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, and similar. "Alkyl" refers to a univalent alkyl radical derived from the removal of a simple hydrogen atom from a straight or branched chain saturated hydrocarbon, and specifically "CT-Ca-alkyl" refers to an alkyl group comprising one to three carbon atoms, including, methyl, ethyl, n-propyl and isopropyl, "Ci-Ce-alkyl" or "alkyl of one to six carbon atoms" refers to an alkyl group comprising one to six carbon atoms. "C ^ Cs-alkyl" includes methyl, ethyl, n-propyl and isopropyl; "d-Cβ-alkyl" or "alkyl of one to six carbon atoms" includes all the previous examples, as well as butyl, butyl, t-butyl, pentyl, neopentyl, hexyl and the like. "Alkenyl" refers to a univalent alkyl radical derived from the removal of a single hydrogen atom from a straight or branched chain hydrocarbon containing one or more double bonds. Examples of alkenyl groups include ethenyl, propenyl, butenyl, isobutenyl, pentenyl, hexenyl, heptenyl, hexadienyl and the like. "Alkylamino" refers to an alkyl group, as previously defined, attached to the parent molecular moiety through an NH-linking group. Examples of Ci-Cs-alkylamino comprising an alkyl of one to three carbon atoms attached to the NH group, include methylamino, ethylamino, n-propylamino and isopropylamino. "Alkynyl" refers to a univalent alkyl radical derived from the removal of a simple hydrogen atom from a straight or branched chain hydrocarbon containing one or more triple bonds. Examples of alkynyl groups include ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, and the like. The term "aryl", as used herein, refers to unsubstituted carbocyclic aromatic groups including, but not limited to, phenyl, 1- or 2-naphthyl, biphenyl, and the like. The term "aryl-Ci-Cβ-alkyl" refers to a d-Ces-alkyl group as defined above, substituted by replacing one of the hydrogen atoms in the alkyl group with an aryl group, as defined herein .
Dialkylamino refers to two alkyl groups, as previously defined, attached to the parent molecular moiety through an N-atom linking group. Examples of dialkylamino groups of one to three carbon atoms include dimethylamino, diethylamino, di-n -propylamino, and di-isopropylamino. "Haloalkyl" refers to an alkyl group, as defined above, of one to six carbon atoms substituted by one or more halogen atoms and includes, for example, trifluoromethyl, chloroethyl, bromobutyl, and the like. The term "heteroaryl", as used herein, refers to a cyclic aromatic radical having from five to ten ring atoms of which, a ring atom is selected from S, O and N; zero, one or two ring atoms are additional heteroatoms independently selected from S, O and N; and the remaining ring atoms are carbon, the radical being joined to the rest of the molecule via any of the ring atoms, including, but not limited to, furyl, thienyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, indolyl, thiazolyl, oxazolyl, isoxazolyl, thiadiazolyl, oxadiazolyl, quinolinyl, isoquinolinyl, and the like. The term "heteroaryl-Ci-Ce-alkyl" refers to a d-Cß-alkyl group as defined above, substituted by replacing one of the hydrogen atoms in the alkyl group with a heteroaryl group, as defined above. The term "hydroxyalkyl" refers to an alkyl group, as defined above, substituted with one or more hydroxy groups. Examples of hydroxyalkyl include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxypentyl and the like. "Substituted alkenyl" refers to an alkenyl group, as defined above, substituted with one or more groups selected from halogen, hydroxy, alkoxy, amino, alkylamino or dialkylamine, CN and the like. Examples of substituted alkenyl groups include methoxyethenyl, chloropropenyl, dimethylaminobutenyl and the like. "Alkenyl substituted" refers to an alkynyl group, as defined above, substituted with one or more groups selected from halogen, hydroxy, alkoxy, amino, alkylamino, or dialkylamino, CN and the like.
Examples of substituted alkynyl groups include methoxyetinyl, chloropropinyl, dimethylaminobutinyl and the like. The term "substituted aryl", as used herein, refers to an aryl group as defined above, substituted with one or two substituents independently selected from the group consisting of alkyl of one to six carbon atoms, haloalkyl of one to six carbon atoms, alkoxy of one to six carbon atoms, alkoxyalkyl, in which, the alkoxy and alkyl portions are independently from one to six carbon atoms, alkoxyalkoxy, in which the alkoxy portions are independently one to six carbon atoms, halogen, cinna, hydroxy, amino, alkylamino of one to six carbon atoms, carboxyl, and alkoxycarbonyl of two to six carbon atoms. A preferred substitution is by replacement of 1 to 2 hydrogen atoms with
F, Cl, Br, d-Cs-alkyl, as defined above, or C ^ Cs-alkoxy. Examples of substituted aryl radicals include, but are not limited to, 4-methylphenyl, 4-chlorophenyl, 4-methoxyphenyl, 4-bromophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 4-methyl-1-naphthyl and 8-chloro -2-naphthyl. The term "substituted heteroaryl" as used herein, refers to a heteroaryl group as defined above, substituted with one or two substituents independently selected from the group consisting of alkyl of one to six carbon atoms, haloalkyl of one to six carbon atoms, alkoxy of one to six carbon atoms, alkoxyalkyl, in which the alkoxy and alkyl portions are independently from one to six carbon atoms, alkoxyalkoxy in which the alkoxy portions are independently from one to six atoms carbon, halogen, cinna, hydroxy, amino, alkylamino of one to six carbon atoms, carboxyl, and alkoxycarbonyl of two to six carbon atoms. There may be one or more asymmetric centers in the compounds of the present invention. Unless otherwise noted, the present invention contemplates the various stereoisomers and mixtures thereof. As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of current medical judgment, suitable for use in contact with the tissues of human and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable risk / benefit ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describe pharmaceutically acceptable salts in detail in J \ Pharmaceutical Sciences, 66: 1-9 (1977), incorporated herein by reference. The salts can be prepared in situ during the isolation and final purification of the compounds of the invention, or separately by reacting the free base function with a suitable organic acid. Examples of pharmaceutically acceptable, non-toxic acid addition salts are salts of an amino group formed with organic acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids, such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art, such as, ion exchange. Other pharmaceutically acceptable salts include salts of adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorrate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, gluconate, hemisulfate , heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like. Representative alkaline or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium and the like. Additional pharmaceutically acceptable salts include, when appropriate, non-toxic ammonium, quaternary ammonium and amine cations formed using counterions, such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkylsulfonate and aryl sulfonate. The term "promedication" refers to compounds that rapidly transform in vivo to produce the parent compounds of Formula (I), as for example, by hydrolysis in the blood. T. Higuchi and V. Stella provide an extensive discussion of the concept of promediation in Prodrugs as Novel Delivery Systems, (Promedications as novel delivery systems) Vol. 14 of A. C.S. Symposium Series, American Chemical Society (1 975). Examples of esters useful as prodrugs for compounds containing carboxyl groups can be found on pages 14-21 of Bioreversible Carriers in Drug Design: Theory and Application, (Bio-reversible carriers in drug design: theory and application), edited by EB Roche, Pergamon Press (1 987). The term "prodrug ester group" refers to any of the various ester-forming groups that are hydrolyzed under physiological conditions. Examples of ester groups of averaly include pyroloxymethyl, acetoxymethyl, phthalidyl, indanyl and methoxymethyl, as well as other such groups known in the art. As used herein, the term "pharmaceutically acceptable ester" refers to esters, which are hydrolyzed in vivo and include those that are easily broken in the human body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl portion suitably has no more than 6 carbon atoms. Examples of particular esters include formats, acetates, propionates, butyrates, acrylates and ethylsuccinates. The pharmaceutical compositions of the present invention comprise a therapeutically effective amount of a compound of the present invention formulated together with one or more pharmaceutically acceptable carriers. As used herein, the term "pharmaceutically acceptable carrier" means an encapsulating material, diluent, liquid or semi-solid filler, inert solid, non-toxic or formulation aid of any kind. Some examples of materials, which can serve as pharmaceutically acceptable carriers are sugars, such as lactose, glucose and sucrose.; starches, such as, corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; jelly; talcum powder; excipients, such as cocoa butter and suppository waxes; oils, such as, peanut oil, cottonseed oil; safflower oil; Sesame oil; olive oil; corn oil and soybean oil; glycols, such as a propylene glycol; esters, such as ethyl oleate and ethyl laurate; agar, buffering agents, such as, magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline solution; Ringer's solution; ethyl alcohol, and phosphate buffers, as well as other non-toxic compatible lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents; sweetening, flavoring and flavoring agents, preservatives and antioxidants, according to the formulator's judgment. The pharmaceutical compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), buccally, or as an oral or nasal spray. Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemutions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, peanut, corn, germ, olive, castor bean and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and esters of sorbitan fatty acids, and mixtures thereof. In addition to the inert diluents, the oral compositions may also include auxiliaries, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and flavoring agents. Injectable, sterile, injectable preparations, for example aqueous or oily suspensions, can be formulated according to the known art using suitable wetting or dispersing agents and suspending agents. The sterile injectable preparation can also be a sterile injectable solution, suspension or emulsion in a non-toxic, parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the vehicles and acceptable solvents that can be used are water, Ringer's solution, U. S. P. and isotonic sodium chloride solution. In addition, sterile, sterile oils are conventionally employed as a solvent or suspending medium. For this purpose, any soft fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids, such as oleic acid, are used in the preparation of injectables. The injectable formulations can be sterilized, for example, by filtration through a filter that retains bacteria, or by incorporating sterilizing agents in the form of sterile solid compositions, which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use. In order to enhance the effect of a medicament, it is often desirable to decrease the absorption of the drug from subcutaneous or intramuscular injection. This can be achieved by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of drug absorption then depends on its rate of dissolution which, in turn, may depend on the crystal size and the crystalline form. Alternatively, the delayed absorption of a parenterally administered drug form is achieved by dissolving or suspending the medicament in an oily vehicle. Injectable depot forms are made by forming microencapsulated matrices of the medically biodegradable polymers, such as, polylactide-polyglycolide. Depending on the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly (orthoesters) and poly (anhydrides). Depot injectable formulations are also prepared by trapping the medically in liposomes or microemulsions, which are compatible with body tissues. Compositions for rectal or vaginal administration are preferably suppositories, which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers, such as cocoa butter, polyethylene glycol or a suppository wax, which are solid to room temperature but liquid at body temperature, and therefore, they melt in the rectum or vaginal cavity and release the active compound. Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is mixed with at least one pharmaceutically acceptable excipient or carrier, inert, such as sodium citrate or dicalcium phosphate and / or to) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol and silicic acid, b) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and gum arabic, c) humectants, such as, glycerol, d) disintegrating agents, such as, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents, such as paraffin, f) absorption accelerators, such as quaternary ammonium compounds, g) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents, such as bentonite clay and kaolin, and i) lubricants, such as, talc, calcium stearate, mag stearate solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents. Solid compositions of a similar type can also be employed as fillings in soft and hard filled gelatin capsules, using excipients such as lactose or milk sugar, as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, "dragees", capsules, pills and granules can be prepared with coatings and shells, such as, enteric coatings and other coatings well known in the art of pharmaceutical formulations. Optionally, they may contain opacifying agents and may also be of a composition that they may release the active ingredient (s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embossed compositions, which may be used, include polymeric substances and waxes. Solid compositions of a similar type can also be used as fillers, in soft and hard filled gelatin capsules using excipients such as lactose or milk sugar, as well as high molecular weight polyethylene glycols and the like. The active compounds can also be in a micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills and granules can be prepared with coatings and shells, such as enteric coatings., release control coatings and other coatings well known in the art of pharmaceutical formulations. In such solid dosage forms, the active compound can be mixed with at least one inert diluent, such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, for example tableting lubricants and other tableting aids, such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and may also be of a composition that releases the active ingredient (s) alone, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embossed compositions, which may be used, include polymeric substances and waxes. Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is mixed under sterile conditions with a pharmaceutically acceptable carrier and any necessary preservative or buffer as may be required. Ophthalmic formulation, eardrops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention. The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as vegetable and animal fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid. , talc and zinc oxide, or mixtures thereof. The powders and sprays may contain, in addition to the compounds of this invention, excipients, such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. The atomizers may additionally contain customary propellants, such as chlorofluorohydrocarbons. Transdermal patches have the additional advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in an appropriate medium. Absorption intensifiers can also be used to increase the flow of compound through the skin. The speed can be controlled either by providing a speed controlling membrane or by dispersing the compound in a gel or polymer matrix. According to the methods of treatment of the present invention, disorders in synaptic transmission are treated or prevented in a patient, such as a human or minor mammal, by administering to the patient a therapeutically effective amount of a compound of the invention, in such quantities and for such a time as necessary to achieve the desired result. By a "therapeutically effective amount" of a compound of the invention is meant a sufficient amount of the compound to treat disorders in synaptic transmission, at a reasonable risk / benefit ratio applicable to any medical treatment. However, it will be understood that the total daily use of the compounds and compositions of the present invention will be decided by the attending physician within the scope of the current medical judgment. The specific therapeutically effective dose level for any particular patient will depend on a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the administration time, route of administration and rate of excretion of the specific compound employed; the duration of the treatment; medications used in combination or coincident with the specific compound used; and similar factors well known in the medical arts. The total daily dose of the compounds of this invention administered to a human or other mammal in single or divided doses may be in amounts, for example, from 0.001 to 50 mg / kg of body weight or more usually, from 0.01 to 25 mg. / kg of body weight. The single dose compositions may contain such amounts or submultiples thereof to make the daily dose. In general, treatment regimens according to the present invention comprise administering to a patient in need of such treatment from about 1 mg to about 1000 mg of the compound or compounds of this invention per day in single or multiple doses. In a preferred embodiment of the present invention, there are provided compounds of Formula (I) above, wherein A is selected from options (a) and (c). In a more preferred embodiment of the present invention, there are provided compounds of Formula (I) above, wherein A is selected from option (c). Representative of the compounds of the invention are: 7a- (3-methyl-5-isoxazolyl) -hexahydro-1 H-pyrrolizine; 7a- (1 H-3-methyl-5-pyrazo I il) -hexahydro-1 H-pyrrolizine; 7a- (3-pyridinyl) -hexahydro-1 H-pyrrolizine; 7a- (3-quinolinyl) -hexahydro-1 H-pyrrolizine; 7a- (6-chloro-3-pyridinyl) -hexah id ro-1 H-pyrrolizine; 7a- (2-fluoro-3-pyridinyl) -hexahydro-1 H -pyrrolizine; 7a- (2-chloro-3-pyridinyl) -hexahydro-1 H -pyrrolizine; 7a- (5,6-dichloro-3-pyridinyl) -hexah id ro-1 H-pyrrolizine; 7a- (5-pyrimidinyl) -hexahydro-1 H -pyrrolizine; 7a- (2,6-difluoro-3-pyridinyl) -hexahydro-1H-pyrrolizine; 7a- (2,6-dichloro-3-pyridinyl) -hexahydro-1 H-pyrrolizine; 7a- (6-f luoro-3-pyridinyl) -hexah id ro-1 H-pyrrolizine;
7a- (3-eti l-5-isoxazo I i l) -hexah id ro-1 H-pyrrolizine; 7a- (3-propyl-5-isoxazolyl) -hexahydro-1 H -pyrrolizine; 7a- (3-benzyl-5-isoxazo I i) -hexah id ro-1 H-pyrrolizine; 7a- (5-hydroxy-3-pyridinyl) -hexahydro-1 H -pyrrolizine; 7a- (5-benzyloxy-3-pyridinyl) -hexahydro-1 H -pyrrolizine; 7a- (5-bromo-3-pyridinyl) -hexahydro-1 H-pyrrolizine; 7a- (6-fluoro-5-methyl-3-pyridinyl) -hexahydro-1 H -pyrrolizine; 7a- (6-chloro-5-methyl-3-pyridinyl) -hexahydro-1 H-pyrrolizine; 7a- (6-methyl-3-pyridinyl) -hexahydro-1 H-pyrrolizine; 7a- (5-methyl-3-pyridinyl) -hexahydro-1 H-pyrrolizine; 7a- (5-bromo-6-fluoro-3-pyridinyl) -hexahydro-1 H -pyrrolizine; 7a- (5-chloro-6-fluoro-3-pyridinyl) -hexahydro-1 H -pyrrolizine; 7a- (4-methyl-3-pyridinyl) -hexahydro-1 H -pyrrolizine; 7a- (5-phenyl-3-pyridinyl) -hexahydro-1 H-pyrrolizine; and or a pharmaceutically acceptable salt or prodrug thereof. Also included within the scope of the present invention are pharmaceutical compositions comprising one or more of the compounds of formula (I) prepared and formulated in combination with one or more non-toxic pharmaceutically acceptable compositions, in the manner described below. Compositions suitable for parenteral injection may comprise aqueous, non-aqueous, sterile, pharmaceutically acceptable solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution in sterile injectable solutions or dispersions. Examples of suitable carriers, diluents, solvents or aqueous and non-aqueous vehicles include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by maintenance of the required particle size in the case of dispersions, and by the use of surfactants. These compositions may also contain auxiliaries, such as preservatives, humectants, emulsifiers and dispersants. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example, sugars, sodium chloride and the like. The prolonged absorption of the injectable pharmaceutical form can be caused by the use of absorption retarding agents, for example, aluminum monostearate and gelatin. If desired, and for a more effective distribution, the compounds can be incorporated in focused delivery or slow release systems, such as polymer matrices, Mposomes and microspheres. They can be sterilized, for example, by filtration through a bacteria retainer filter, or by incorporating sterilizing agents in the form of sterile solid compositions, which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
Solid dosage forms for oral administration may include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is mixed with at least one customary inert (or carrier) excipient, such as, sodium citrate or dicalcium phosphate, and additionally (a) fillers or extenders, such as, for example, starches, lactose , sucrose, glucose, mannitol and silicic acid; (b) binders, such as, for example, carboxymethyl cellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and gum arabic; (c) humectants, such as, for example, glycerol; (d) disintegrating agents, such as, for example, agar-agar, calcium carbonate, potato starch or tapioca, algic acid, certain complex silicates and sodium carbonate; (e) solution retardants, such as paraffin; (f) absorption accelerators, such as, for example, quaternary ammonium compounds; (g) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; (h) adsorbents, such as, for example, kaolin and bentonite; e (i) lubricants, such as, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillings in soft and hard filled gelatin capsules, using excipients such as lactose or milk sugar, as well as high molecular weight polyethylene glycols, and the like. Solid dosage forms, such as, tablets, dragees, capsules, pills and granules can be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may contain pacifying agents, and may also be a composition such that it releases the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embossed compositions, which may be used are polymeric substances and waxes. The active compounds may also be in microencapsulated form, if appropriate, with one or more of the aforementioned excipients. Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, such as, for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate. , benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils, in particular, cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and oil. sesame, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and esters of sorbitan fatty acids or mixtures of these substances, and the like. In addition to such inert diluents, these liquid dosage forms may also include auxiliaries, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and flavoring agents.
The suspensions, in addition to the active compounds, may contain suspending agents, such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances and similar. Compositions for rectal or vaginal administration are preferably suppositories, which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers, such as cocoa butter, polyethylene glycol or a suppository wax, which are solids at ordinary temperatures but liquid at body temperature, and therefore, they melt in the rectum or vaginal cavity and release the active component. Dosage forms for topical or transdermal administration of a compound of this invention also include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or transdermal patches. Transdermal administration via a transdermal patch is a preferred and particularly effective dosage form of the present invention. The active component is mixed under sterile conditions with a pharmaceutically acceptable carrier and any necessary preservative, buffer or propellant as may be required. It is known that some agents may require special handling in the preparation of transdermal patch formulations. For example, compounds that are volatile in nature may require mixing with special formulation agents or with special packaging materials to ensure delivery of the appropriate dosage.
In addition, compounds that are absorbed very rapidly through the skin may require a formulation with agents or retarding absorption barriers. Ophthalmic formulations, powders, solutions and eye ointments are also contemplated within the scope of this invention. The present compounds can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. The liposomes are formed by mono- or multilamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any metabolizable, physiologically acceptable and non-toxic liquid capable of forming liposomes can be used. The present compositions in liposome form may contain, in addition to the compounds of the present invention, stabilizers, preservatives, excipients and the like. The preferred lipids are phospholipids and phosphatidylcholines (lecithins), both natural and synthetic. Methods for forming liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, volume XIV, Academic Press, New York, N.Y. , (1976), p 33 et seq. In order to reduce unwanted peripherally mediated side effects, it is desirable, but not essential, to incorporate an anti-cholinergic that acts peripherally, such as, N-methylcopolamine, N-methylatropine, propanthelin, metanyl or glycopyrrolate into the composition. .
Synthetic Methods The compounds of the present invention can be synthesized as shown in Reaction Schemes I and I I presented below using the reactions and techniques described in this section. The reactions are carried out in a suitable solvent for the reagents and the materials used are suitable for the transformation that is taking place. Those skilled in the art of organic synthesis understand that the functionality present in the heterocyclic ring and other portions of the molecule must be consistent with the proposed chemical transformation. This will need, in due course, the practitioner's judgment in order to decide the order of the synthetic steps, required protective groups and conditions of deprotection. The substituents in the starting materials may be incompatible with some of the reaction conditions required in some of the described methods, but alternative methods and substituents compatible with the reaction conditions will be readily apparent to practitioners skilled in the art. The use of nitrogen protecting groups is well known in the art for protecting amino groups against undesirable reactions during a synthetic process and many such protective groups are known, cf. , for example, T.H. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 2nd edition, John Wiley & amp; amp;; Sons, New York (1 991).
Esguema 1
1 2 According to Scheme 1, compounds of Formula (I) are prepared, wherein A is selected from options (c) - (g), as described above. A compound AX, wherein A is selected from options (c) - (g), as described above, and wherein X is I or Br, is treated with an alkyl lithium, for example, n-butyllithium or t-butyllithium , at a temperature of about -100 ° C to -28 ° C, to give a compound A-Li, for example,
wherein RO, R and R are as previously defined for compounds of Formula (I). The compound A-Li is reacted with the compound (1), a starting material prepared according to the procedure of Miyano et al. (Synthesis, 701 (1978)), starting the reaction at a temperature from about -100 ° C to -70 ° C and heating at a temperature from -30 ° C to ambient, in a suitable solvent, such as ether or THF , for example, for a period of from 0.2 to 24 hours to give the desired compounds (2), which are specific examples of Formula (I) above. Alternatively, when R3, R4 or R5 is F, Cl or Br, particularly when substituted at a ring position adjacent to a ring nitrogen atom, any may be displaced by another nucleophile, eg, a different halogen, ammonia or an amine, a C ^ Cs-alkoxide, or a C ^ Cs-thiolate to give additional compounds of Formula (I) above. A primary amino group can be further modified by acylation with suitably activated carboxylic, carbonic or carbamic acid, or by conversion to hydrosi using a diazotization / hydrolysis sequence, or to halo, by a diazotization / halide displacement, for example, under Sandmeyer well known, or nitro by oxidation, for example, with hydrogen peroxide in sulfuric acid.
Scheme 2
by transition metal
Alternatively, as illustrated in Scheme 2, R3 or R4 may be a group G, where G is a sulfonate, for example O-SO2CF3, or halo, particularly bromine or iodine, which is replaceable by a variety of groups functional with the help of transition metal catalysis using methods well known to those skilled in the art. In this way, the reaction of compound (3) with Zn (CN) 2 with the aid of palladium and heat catalysis and a suitable solvent, such as DMF or N-methylpyrrolidinone, provides compounds I (R3 = CN). Moreover, using well established methods, the cyano group can be further transformed, for example, reduction (to -CH2NH2), or by hydrolysis (to CO2H), or by reaction with any of a variety of organometallic agents followed by hydrolysis (for give ketones), or by cycloaddition of 1, 3-dipolabafilos (to give heterocycles). The -CH2NH2 group can be further modified by alkylation with an alkyl halide, or alternatively by reaction with an aldehyde or ketone under reducing conditions, or by acylation with a suitably activated carboxylic, carbonic or carbamic acid. Alternatively, replacement of G with aryl, substituted aryl, heteroaryl or substituted heteroaryl can be achieved by the reaction of (3) with the appropriate aryl or heteroarylboronic acid under palladium catalysis in a suitable solvent, such as benzene, toluene, DMF. , THF or similar, at temperatures from approximately 40 ° C to 120 ° C. Replacement of G with substituted akenyl, alkenyl, dienyl or substituted dienyl can be achieved by reaction of (3) with the appropriate alkene or diene under Heck conditions, ie, under palladium catalysis in a suitable solvent, such as benzene, toluene, DMF, THF or the like, at temperatures from about 40 ° C to 120 ° C. Replacement of G with alkynyl or substituted alkynyl can be achieved by reaction of (3) with the appropriate alkyne or alkyne substituted under palladium catalysis in the presence of a Cu (I) salt and a base such as a tertiary amine, by example, triethylamine, in a suitable solvent, such as benzene, toluene, DMF, THF or the like, at temperatures from about 40 ° C to 120 ° C. The alkenes or alkynes obtained as described above, can be reduced to alienes by appropriate hydrogenation techniques, such as, treatment with hydrogen on a noble metal catalyst.
Esguema 3
T T R1-CH2-NO2 + Ph-NCO R ^ C = N-O 4 5
1 7 6 8 According to Scheme 3, compounds of Formula (I) are prepared, wherein A is selected from option (a) as described above. Compound (7) was first prepared from compound (1) by treatment with ethynylmagnesium bromide under the conditions described for Scheme 1 above. In the presence of the acetylene compound (7), the nitrile-oxide compound (6) is generated from a nitro compound (4), wherein R1 is as previously described, by reaction with phenylisocyanate (5) in benzene or toluene, for example, from 60 ° C to the reflux temperature of the solvent for 6 to 24 hours, and the compounds (6) and (7) react to give the desired isoxazolyl compound (8), which also it is a specific specimen of Formula (I). According to Scheme 4 below, compounds of Formula (I) are prepared, wherein A is selected from options (a) and (b) above, wherein R 1 is methyl. A protected proline carboxylic ester (9) is reacted with LDA at -78 ° C to 0 ° C, and then with allyl bromide at a temperature from -78 ° C to room to give the pyrrolidine compound substituted with allyl ( 10). Compound (10) is selectively hydrated at the terminal carbon atom by sequential treatment with BH3 and H2O2. The intermediate alcohol is then mesylated by treatment with methanesulfonyl chloride in the presence of base to give the compound (11). The compound (1) is deprotected by standard methods, such as, removal of carbobenzoxy with hydrogen in the presence of palladium catalyst, for example, which also induces cyclization to provide the bicyclic compound (12). The compound (12) is then treated with the dilithium anion of acetone oxime (of course, other oximes can be produced from the corresponding ketone to vary R1 in accordance), and the intermediate compound is cyclized by treatment with dehydrating conditions, such as , H2SO4, to give the compound (13), also a representative example of Formula (I). Alternatively, compound 12 is treated with the dilithium anion of acetone oxime, then treated with an appropriately substituted hydrazine to give compound (14), wherein R2 is as described by compounds of Formula (I), previously , which is also a representative example of Formula (I). Esguema 4
e 1 2 1 3
A. Protocol for determination of ligand-nicotinic acetylcholine receptor binding strengths In order to identify compounds as cholinergic agents, which are capable of interacting with nicotinic acetylcholine receptors in the brain, a ligand-receptor binding assay was performed as the initial screen. The compounds of the present invention were effective in interacting with neuronal nicotinic acetylcholine receptors as tested for their ability to displace radioligand from neuronal nicotinic acetylcholine channel receptors labeled with [3H] -cystine ([3H] -CYT). Displacement of [3H] -CYT of nicotinic acetylcholine receptors was determined using crude rat whole brain synaptic membrane preparations (Pabreza et al., Molecular Pharmacol., 1990, 39: 9). The washed membranes were stored at -80 ° C before use. The frozen aliquots were thawed slowly and resuspended in 20 buffer volumes (containing: 120 mM NaCI, 5 mM KCI, 2 mM MgCl2, 2 mM CaCl2 and 50 mM Tris-CI, pH 7.4 @ 4 ° C). After centrifugation at 20,000 x g for 15 minutes, the pellets were resuspended in 30 volumes of buffer. The homogenate (containing 125-150 μg of protein) was added to triplicate tubes containing concentrations of the test compound and [3 H] -CYT (1.25 nM) in a final volume of 500 μl. The samples were incubated for 60 minutes at 4 ° C, then quickly filtered through Whatman GF / B filters in 0.5% polyethylimine using 2 x 4 ml of ice-cold buffer. The filters were counted in 4 ml of Ecolume® (ICN). Non-specific ligation was determined in the presence of 10 μM (-) - nicotine and the values were expressed as a percentage of total ligation. The IC50 values were determined with the non-linear least squares curve adjustment program RS-1 (BBN) and the IC50 values were converted to Ki values using the Cheng and Prusoff correction (Ki = IC50 / 1 + [ligand] / Kd of ligand). Alternatively, the data were expressed as a percentage of the total specific binding. The results (shown in Table 1) suggest that the compounds of the present invention have high affinity for the neuronal nicotinic acetylcholine receptor.
B. Protocols for the determination of functional effects of nicotinic acetylcholine receptor ligands on synaptic transmission The ability of the compounds of the invention to interact with neuronal nicotinic acetylcholine receptors and thereby activate or inhibit synaptic transmission can be demonstrated in vitro using The following protocol. The cells of the human neuroblastoma clonal cell line I MR-32 (ATCC, Rockville, MD) were maintained in a logarithmic growth phase according to established procedures (Lukas, 1993). The experimental cells were seeded at a density of 500,000 cells / ml in a 24-well tissue culture plate. The platinum cells were allowed to proliferate for at least 48 hours before loading with 2 μCi / ml of 86Rb + (35 Ci / mmol) overnight at 37 ° C. The 86Rb + effluvium assays were performed according to previously published protocols (Lukas, RJ m J. Pharmacol, Exp. Ther., 265: 294-302, 1993) except that Dulbecco's modified serum-free Eagle's medium was used for the load steps of 86Rb +, rinse and effluvium induced by agonist. The responses (reported as percent relative to the response produced by 100 μM of (S) -nicotine) are shown for the indicated concentrations of the selected compounds of the invention. The inhibition data (given by other selected compounds) reflect the inhibition of the effluvium produced by 1 00 μM of (S) -nicotine at the indicated concentration. The results (also shown in Table 1) suggest that the selected compounds of the present invention either activate or inhibit aspects of initial ion fluxes of synaptic transmission mediated by neuronal nicotinic acetylcholine receptors. This finding is in agreement with the results of others, who have linked the release of dopamine, which is dependent on the flow of ions in synaptic transmission, to bind to nicotinic receptors (cf., for example, Lippiello and Caldwell, US Pat. 5,242, 935, issued September 7, 1993; Caldwell and Lippiello, U.S. Patent 5,248,690, issued September 28, 1993; and Wonnacott et al., Prog. Brain Res., 79: 1 57-163 (1 989)).
Table 1 Ligation to neuronal nicotinic acetylcholine receptors and activation or inhibition of neuronal nicotine acetylcholine receptors in IMR-32 cells Ex. No. Ligature (nM) IMR-32 IMR-32% response% inhibition (conc.) (Conc.)
1 0.97 110 (10 μM) 2 70 3 0.38 71 (10 μM) 4 4.3 40 (10 μM) 5 0.10 82 (1 μM) 6 5.7 7 436 8 0.055 71 (1 μM) 9 3.7 39 (100 μM) 10 2.9 13 (10 μM) 12 (10 μM)
11 1417 12 0.27 93 (10 μM) 13 1.4 108 (100 μM) 14 1.7 74 (100 μM) 15 4.0 16 1.4 53 (100 μM) 16b 0.27 17 0.61 41 (10 μM) 18 0.11 66 (10 μM) 19 0.05 91 (1 μM) 20 0.56 98 (1 μM) 21 0.33 56 (1 μM) 22 0.22 42 (10 μM) 23 0.23 68 (10 μM) 24 72 0 (100 μM) 14 (10 μM)
In addition, the compounds of the invention are useful as binders for the a7-nicotinic acetylcholine receptor, which is a useful indicator for treating certain forms of psychosis, for treating certain forms of cognitive deficits, or as neuroprotective agents. Compounds (1-14, 16b, 20, 21 and 25) exhibited a binding affinity relative to the known bungarotoxin binder alpha7 of between 0.9-16.200 nM. Accordingly, the compounds bind to several nicotinic receptor subtypes. The present invention is therefore directed to a compound of formula I or a pharmaceutical composition thereof, which binds both the alpha4beta2 receptor and the alpha7 receptor in mammals including humans, and a method for binding either or both subtypes of receptors comprising administering a pharmaceutically effective amount of said compound or salt thereof in an in vitro or in vivo screen or to a patient in need of treatment thereof.
EXAMPLES The following examples will serve to further illustrate the preparation of the novel compounds of the invention and their biological activity. They are not to be read as limiting the scope of the invention, as defined by the appended claims. Thin layer chromatography (TLC) was performed on 0.25 mm E. Merck pre-coated silica gel plates (60 F-254). Flash chromatography on 200-400 mesh silica gel (E. Merck) was performed, and column chromatography on 70-230 mesh silica gel (E. Merck) was performed. The following abbreviations are used: THF for tetrahydrofuran, DMF for N, N-dimethylformamide, D2O for deuterium oxide, CDCI3 for deuteriochloroform, DMSO-d6 for deuterodimethylsulfoxide, BOC for tert-butyloxycarbonyl, CBZ for benzyloxycarbonyl, Bn for benzyl, MS for methanesulfonyl, PAW for pyridine / acetic acid / water (20: 6: 1 1), DCC for dicyclohexylcarbodiimide, DI BALH for diisobutylaluminum hydride, DI EA for diisopropylethylamine, DME for 1,2-dimethoxyethane, DMSO for dimethylsulfoxide; DPPA for diphenylphosphorayl azide, EDCI for (1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride, EtOAc for ethyl acetate, HOBT for 1-hydroxybenzotriazole, LAH for lithium aluminum hydride, NH4OAc for ammonium acetate, dppp for 1 , 3-bis (diphenylphosphino) propane, NMM for N-methylmorpholine, TEA for triethylamine, THF for tetrahydrofuran.
EXAMPLE 1 7a- (3-Met-il-5-is-oxazole-1-hydroxychloride) -hexah id ro-1 H-pyrrolizine
1 a. 1-benzyloxycarbonyl-2- (methoxycarbonyl) -2- (2-propenyl) pyrrolidine Under a nitrogen atmosphere, diisopropylamine (16.4 ml, 11.1 mmol) was dissolved in THF (17 ml) and cooled to -78 ° C. C. Then a solution of 2.5 M of n-butyllithium in hexane (43 ml, 1 07.5 mmol) was added in the form of drops, followed by stirring for 15 minutes and then 1-benzyloxycarbonylproline methyl ester (25.7 g, 97.7 mmol) was added. in THF (575 ml) to the reaction vessel in the form of drops over a period of 40 minutes. The reaction mixture was allowed to stir for 15 minutes at -78 ° C, pure allyl bromide (25.4 ml, 293 mmol) was added at a stable rate, followed by stirring for 15 minutes at -78 ° C and for 2 additional hours between -35 ° C and -25 ° C. Then, a phosphate buffer solution (-100 ml), pH = 7, was poured into the reaction vessel and the reaction mixture was allowed to warm to room temperature. The mixture was diluted with EtOAc, washed in succession with 2N HCl and brine, dried (Na2SO4) and concentrated. The residue was subjected to chromatography (silica gel; EtOAc / hexane 1:20 to 1:15 to 1:10) to give a yellow oil (17.8 g, 63%). Rf 0.31 (EtOAc / hexane, 1: 4). MS (CI / NH3) m / e: 304 (M + H) +. 1 H NMR (DMSO-d 6, 300 MHz) d 1.77-1.86 (m, 2H), 1.94-2.13 (m, 2H), 2.50-2.59 (m, 1H partially buried under DMSO), 2.84 minor former and 2.92 major former ( dd, J = 14.0 Hz, 7.0 Hz, 1H), 3.28-3.62 (m, 5H), 4.96-5.11 (m, 4H), 5.64-5.75 (m, 1H), 7.27-7.41 (m, 5H).
1 B. 1-Benzyloxycarbonyl-2- (3-hydroxypropyl) -2- (methoxycarbonyl) pyrrolidine 1-benzyl oxy-carbon il-2- (methoxycarbonyl) -2- (2-pro peny I) pyrrolidine was dissolved (from step 1a, 21.0 g, 69.4 mmol) in THF (70 ml) and borane complex 1.0 M THF (45 ml, 45 mmol) was added dropwise to the reaction vessel over a period of 40 minutes. The reaction mixture was allowed to stir for one hour, then ~ 10 ml of water was added carefully followed by the successive addition of 3 N NaOH (16.2 ml, 48.5 mmol) and 30% hydrogen peroxide (5.5 ml, 48.5 mmol). The mixture was allowed to stir for one hour, then was emptied into a separatory funnel containing 250 ml of water and 15 ml of 10% Na2S2O3. The aqueous solution was extracted with CH2Cl2 (3X) and the organic fractions were combined, washed in succession with saturated NaHCO3 and then with brine, dried (Na2SO4) and concentrated. The residue was chromatographed (silica gel; EtOAc / hexane, 1: 4 to 1: 2 to 1: 1 to EtOAc) to give a clear viscous oil (12.3 g, 55% yield). Rf 0.18 (EtOAc / hexane, 1: 1). MS (CI / NH3) m / e: 322 (M + H) +. 1 H NMR (CDCl 3, 300 MHz) d 1.20-2.41 (m, 8H), 3.45-3.82 (m, 7H), 5.06-5.18 (m, 2H), 7.29-7.37 (m, 5H).
1 C. 1-Benzyloxycarbonyl-2- (methoxycarbonyl) -2- (3-methylsulfonyloxy-propyDpyrrolidine) 1-Benzyloxycarbonyl-2- (3-hydroxypropyl) -2- (methoxycarbonyl) pyrrolidine (from step 1b, 10.7 g, 33.2 mmol) was combined and triethylamine (4.9 ml, 34.9 mmol) in THF (133 ml) and cooled to 0 ° C under a nitrogen atmosphere, methanesulfonyl chloride (2.70 ml, 34.9 mmol) was added dropwise to the reaction mixture and stirred for 30 minutes at 0 ° C. Water was added and the contents of the reaction vessel were emptied into a separatory funnel.The mixture was washed in succession with 10% citric acid solution and then with saturated NaHCO3 solution, dried (Na2SO4), concentrated and the residue was chromatographed (silica gel; EtOAc / hexane, 1: 1 to 1: 2) to give a clear oil (11.0 g, 83%). Rf 0.25 (EtOAc / hexane , 1: 1) MS (CI / NH3) m / e: 400 (M + H) + .1H NMR (CDCI3, 300 MHz) d 1.59-2.35 (m, 8H), 2.93 minor former and 2.99 major former ( s, 3H), 3.46-3.80 (m , 5H), 4.07-4.27 (m, 2H), 5.05-5.17 (m, 2H), 7.29-7.36 (m, 5H).
1d. 7 a- (methoxy carbon i) -hexah id ro-1 H-pyrrolizine 1-Benzyloxycarbonyl-2- (methoxycarbonyl) -2- (3-methylsulfonyloxy-propyl) pyrrolidine was dissolved (from step 1c, 11.0 g, 27.6 mmol ) in MeOH and exposed to hydrogen gas at a pressure of 4 atmospheres in the presence of 10% palladium on carbon (11.0 g) for 48 hours. The reaction was filtered and the filtrate was evaporated. The crude was subjected to chromatography (silica gel; CHCl3 / MeOH, 98: 2 to 95: 5 to 90:10) to give a yellow oil (4.23 g, 90%). Rf 0.53 (CHCl3 / MeOH, 90:10). MS (CI / NH3) m / e: 170 (M + H) +. 1 H NMR (CDCl 3, 300 MHz) d 1.24-1.85 (m, 6H), 2.30 ("qt", J = 6.0 Hz, 2H), 2.72 (ddd, J = 9.9 Hz, 6.6 Hz, 6.6 Hz, 2H), 3.23 (ddd, J = 9.9 Hz, 5.9 Hz, 5.9 Hz, 2H), 3.72 (s, 3H).
1e 7a- (3-methyl-5-isoxazolyl) -hexahydro-1 H -pyrrolizine 8- (methoxycarbonyl) -hexahydro-1H-pyrrolizine (from step 1d, 1.56 g, 9.22 mmol), acetone oxime (1.45 g, 19.8 mmol) and n-butyllithium (2.5 M in hexane, 16 ml, 39.6 mmol) in a manner similar to that reported by J. Saunders et al., J. Med. Chem. 1990, 33: 1128. The crude material was subjected to chromatography (silica gel; CHCl3 / MeOH, 99: 1) to give a yellow oil (199 mg, 11%). MS (CI / NH3) m / e: 193 (M + H) +. 1 H NMR (CDCl 3, 300 MHz) d 1.76-1.92 (m, 6 H), 2.14-2.29 (m, 2 H), 2.24 (s, 3 H), 2.61-2.69 (m, 2 H), 3.13-3.32 (m, 2 H) ), 5.95 (s, 1H).
1 f. 7a- (3-Methyl-5-isoxazolyl) -hexahydro-1 H -pyrrolizine hydrochloride. 7a- (3-Methyl-5-isoxazolyl) -hexahydro-1 H -pyrrolizine was submerged (from step 1 e, 1.89 mg, 0.98 mmol) in Et 2 O (7 mL) and cooled to 0 ° C. An Et20 solution saturated with HCl (g) was added to the reaction vessel in the form of drops with stirring. The solvent was carefully removed and the remaining white solid was triturated with Et 2 O (2X) followed by recrystallization out of MeOH / Et 2 O (126.5 mg, 56%). mp 169-171 ° C. MS (CI / NH3) m / e: 1 93 (M + H) +. H NMR (D2O, 300 MHz) d 2.20-2.41 (m, 9H), 2.60-2.68 (m, 2H), 3.31 -3.39 (m, 2H), 3.71 -3.79 (m, 2H), 6.59 (s, 1 H). Anal. Caled for C1 1 H17CIN2O: C, 57.76; H, 7.49; N, 12.25. Found: C, 57.84; H, 7.34; N, 12.13.
Example 2 Di 7a- (1 H-S-methyl-S-pyrazolo-OH-hexahydro-1 H-pyrrolizine hydrochloride
2a. 7a- (1 - (1, 3-butanedione-3-oxim a)) -hexah id ro-1 H-pyrrolizine Butyllithium (1.6 M / hexane, 6.2 ml, 9.88 mmol) was added to an acetone solution of oxime (365 mg, 4.9 mmol) in THF (7.5 ml) previously cooled to 0 ° C. After ten minutes of stirring, 8- (methoxycarbonyl) -hexahydro-1 H -pyrrolizine (from Example 1 d, 645 mg, 3.8 mmol) in THF (7.6 ml) was added and the reaction mixture was allowed to warm to room temperature. room temperature and stirred an additional 8 hours. Saturated N H 4 Cl solution was added, and the phases were separated. Solid K2CO3 was added to the aqueous phase followed by extraction with CHCl3 (3X). The organics were combined, dried (MgSO), concentrated and the crude product was chromatographed (silica gel; CHCl3 / MeOH, 90:10) to give an amber solid (257 mg, 32%). MS (CI / NH3) m / e: 211 (M + H) +.
2b. 7a- (1 H -3-methyl-5-pyrazolyl) -hexahydro-1 H-pyrrolizine Ethanol (2.0 ml) saturated with HCl (g) was added to a solution of the 7a- [1- (1,3-butanedione- 3-oxime)] hexahydro-1H-pyrrolizine (from step 2a, 245 mg, 1.16 mmol) and hydrazine (182 μl, 5.80 mmol) in EtOH (2.5 ml). The reaction mixture was heated to reflux for 3 hours and then allowed to cool to room temperature. Saturated NH CI was added and the phases were separated. Solid K2CO3 was added and the aqueous mixture was extracted with CHCl3. The organic fraction was dried (MgSO4), concentrated and chromatographed (CHCl3 / MeOH / NH4OH, 90: 10: 0 to 90: 9.5: 0.5) to give a solid (97 mg, 44%). mp 56-58 ° C. MS (CI / NH3) m / e: 192 (M + H) +. 1 H NMR (CDCl 3, 300 MHz) d 1.72-1.97 (m, 6 H), 2.02-2.12 (m, 2 H), 2.26 (s, 3 H), 2.61-2.71 (m, 2 H), 3.18-3.26 (m, 2 H) ), 5.82 (s, 1H).
2 C. 7a- (1H-3-Methyl-5-pyrazolyl) -hexahydro-1H-pyrrolizine dihydrochloride salt 7a- (1H, 3-methyl-5-pyrazolyl) -hexahydro-1H-pyrrolizine (from step 2b, 90.0 was dissolved mg, 0.47 mmol) in THF: MeOH (10: 1, 11 mL) and Et2O saturated with HCl (g) was added dropwise. The solvent was removed and the remaining solid was triturated with Et2O (2X) and then recrystallized from MeOH / Et2O to give a white crystalline solid (90.0 mg, 72%).
mp 130-132 ° C. MS (CI / NH3) m / e: 192 (M + H) +. 1 H NMR (D 2 O, 300 MHz) d 2.08-2.33 (m, 9H), 2.50-2.59 (m, 2H), 3.22-3.31 (m, 2H), 3.65-3.74 (m, 2H), 6.27 (s, 1H ). Anal. Caled for CnH ^ CUNa: C, 50.01; H, 7.25; N, 15.90. Found: C, 49.71; H, 7.49; N, 15.77.
Example 3 7a- (3-pyridinium-hexahydro-1H-pyrrolizine hydrochloride
3a. 7a- (3-pi ridi ni l) -hexahydro-1 H-pyrrolizine A solution of n-butyllithium 2.5M in hexanes (2.9 ml) was added, 7.2 mmol) in the form of drops to a solution of 3-bromopyridine (0.690 ml, 7.2 mmol) in Et2O (10 ml) at -78 ° C. After stirring for 10 minutes, 1,2,3,3,5,6,7-hexahydropyrrolizinium perchlorate (500 mg, 2.4 mmol), prepared according to S. Miyano et al., Was introduced into the reaction vessel, Synthesis 1978, 701-702 and S. Miyano et al., Journal of Heterocyclic Chemistry, 1982, 19: 1465-1468, followed by shaking at -78 ° C for 4 hours. The reaction mixture was allowed to warm to room temperature, and 2 N HCl was added. The phases were separated and the aqueous phase was basified with 15% NaOH solution and extracted with CHCl3 (3X). The organic fractions were combined, dried (MgSO4), concentrated and subjected to chromatography (silica gel; CHCl3 / MeOH, 97.5: 2.5) to give an amber oil (260 mg, 58%). Rf = 0.2 (CHCl3 / MeOH, 90:10). MS (CI / NH3) m / e: 189 (M + H) +. 1 H NMR (CDCl 3, 300 MHz) d 1.58-1.76 (m, 2 H), 1.79-1.90 (m, 2 H), 1.92-2.08 (m, 4 H), 2.66-2.74 (m, 2 H), 3.13-3.20 (m , 2H), 7.19 (dd, J = 7.7, 4.8 Hz, 1H), 7.82 (ddd, J = 7.7, 2.6, 1.4 Hz, 1H), 8.41 (dd, J = 4.8, 1.4 Hz, 1H), 8.71 ( d, J = 2.6 Hz, 1H).
3b. 7a- (3-pyridinyl) -hexahydro-1H-pyrrolizine hydrochloride salt 7a- (3-pyridinyl) -hexahydro-1H-pyrrolizine (from step 3a, 125 mg, 0.66 mmol) was dissolved in CH2Cl2 (15). ml) and Et2O saturated with HCl (g) was added dropwise. The solvent was removed, and the remaining solid was triturated with CH2Cl2 (2X) to give a yellow hygroscopic solid (140 mg, 81%). MS (CI / NHs) m / e: 189 (M + H) +. 1 H NMR (D 2 O, 300 MHz) d 2.13-2.29 (m, 2 H), 2.32-2.43 (m, 2 H), 2.48-2.69 (m, 4 H), 3.40 (3.49 (m, 2 H), 3.83-3.92 (m , 2H), 7.92 (dd, J = 8.5, 5.5 Hz, 1H), 8.43 (ddd, J = 8.5, 2.6, 1.4 Hz, 1H), 8.75 (dd, J = 5.5, 1.4 Hz, 1H), 8.88 ( d, J = 2.6 Hz, 1H) Anal Caled for C12H18CI2N2 «0.5H2O: C, 53.34; H, 7.09; N, 10.37 Found: C, 53.28; H, 6.96; N, 10.22.
Example 4 7a- (3-quinolinyl) -hexahydro-1H-pyrrolizine dihydrochloride
4a. 7a- (3-quinolinyl) -hexahydro-1 H -pyrrolizine A solution of 2.5 M nBuLi (1.2 ml, 2.8 mmol) in hexanes was added to 3-bromoquinoline (386 μl, 2.8 mmol) in THF (10 ml) at - 100 ° C followed immediately by 1,2,3,5,6,7-hexahydropyrrolizinium perchlorate (200 mg, 0.9 mmol). The reaction mixture was allowed to stir for 2 hours at -100 ° C and then 2N HCl was added at 0 ° C. After warming to room temperature, the mixture was poured into EtOAc and the phases were separated. The aqueous phase was basified with 15% NaOH solution and extracted with CH2Cl2 (3X). The fractions were combined, dried (MgSO4) and concentrated, and the residue was subjected to chromatography (silica gel; EtOAc) to give a pale solid (104 mg, 46%). mp 80-83 ° C. MS (CI / NH3) m / e: 239 (M + H) +. 1 H NMR (CDCl 3, 300 MHz) d 1.61-1.75 (m, 2 H), 1.83-1.94 (m, 2 H), 2.03-2.17 (m, 4 H), 2.71-2.80 (m, 2 H), 3.20-3.27 (m , 2H), 7.52 (ddd, J = 7.0, 7.0, 1.1 Hz, 1H), 7.65 (ddd, J = 7.0, 7.0, 1.5 Hz, 1H), 7.82 (d, H = 8.1 Hz, 1H), 8.05 ( d, J = 8.5 Hz, 1H), 8.32 (d, J = 2.2, Hz, 1H), 8.97 (d, J = 2.2 Hz, 1H).
4b. 7a- (3-quinolinyl) -hexahydro-1H-pyrrolizine dihydrochloride salt 7a- (3-quinolinyl) -hexahydro-1 H -pyrrolizine (from step 4a, 95 mg, 0.4 mmol) was dissolved in CH 2 Cl 2 (5 ml) , and Et2O saturated with HCl (g) was added to the reaction solution. The solvent was removed and the remaining solid was recrystallized from MeOH / Et2O to give white, short hygroscopic needles (65 mg, 52%). MS (CI / NH3) m / e: 239 (M + H) +. 1 H NMR (D 2 O, 300 MHz) d 2.21-2.49 (m, 4 H), 2.55-2.64 (m, 2 H), 2.72-2.81 (m, 2 H), 3.42-3.51 (m, 2 H), 3.90-3.98 (m , 2H), 7.87 (ddd, J = 7.0, 7.0, 1.1 Hz, 1H), 8.05 (ddd, J = 7.0, 7.0, 1.1 Hz, 1H), 8.17 (m, 2H), 8.85 (d, J = 2.6 Hz, 1H), 9.13 (d, J = 2.6 Hz, 1H). Anal. Cale for C 16 H 20 Cl 2 N 2"1.4 H 2 O: C, 57.11; H, 6.83; N, 8.33. Found: C, 57.17; H, 6.90; N, 8.17.
Example 5 Hydrochloride of 7a- (6-chloro-3-p i ridin i l) -hexah id ro-1 H-pyrrolizine 5a. 7a- (6-Chloro-3-pyridinyl) -hexahydro-1 H -pyrrolizine A 2.5 M solution of nBuLi (1.8 mL, 4.4 mmol) in hexanes was added dropwise to 2-chloro-5-iodopyridine (1.0 g) , 4.2 mmol, prepared according to SC Clayton and AC Regan, Tetrahedron Letters 1993, 34: 7493-7496), was made into Et2O (17 ml) at -78 ° C. After stirring for 15 minutes, 1,2,3,5,6,7-hexahydropyrrolizinium perchlorate (1.0 g, 5.0 mmol) was added, and the reaction mixture was allowed to warm to room temperature. A solution of 2N HCl was added, and the phases were separated. The aqueous phase was basified with 15% NaOH solution and extracted with CH2Cl2 (3X). The organic phases were combined, dried (MgSO4) and concentrated, and the residue was subjected to chromatography (silica gel; CHCl3 / MeOH, 99: 1) to give a yellow oil (219 mg, 23%). Rf = 0.2 (CHCl3 / MeOH, 98: 2). MS (CI / NH3) m / e: 223 (M + H) +. 1 H NMR (CDCl 3, 300 MHz) d 1.58-1.71 (m, 2 H), 1.79-2.08 (m, 6 H), 2.63-2.71 (m, 2 H), 3.11-3.18 (m, 2 H), 7.22 (d, J = 8.5 Hz, 1H), 7.80 (dd, J = 8.5, 2.6 Hz, 1), 8.48 (d, J = 2.6 Hz, 1H).
5b. 7a- (6-Chloro-3-pyridinyl) -hexahydro-1H-pyrrolizine hydrochloride salt 7a- (6-Chloro-3-pyridinyl) -hexahydro-1H-pyrrolizine (from step 5a) was dissolved, 210 mg, 0.94 mmol) in Et 2 O (8 mL), and Et 2 O saturated with HCl (g) was added at room temperature. The solvent was then removed, and the remaining solid was recrystallized from MeOH / Et2O to give short white needles (189 mg, 78%). mp 141-143 ° C. MS (CI / NH3) m / e: 223 (M + H) +. 1 H NMR (D 2 O, 300 MHz) d 2.12-2.50 (m, 6H), 2.58-2.65 (m, 2H), 3.33-3.42 (m, 2H), 3.69-3.88 (m, 2H), 7.62 (d, J = 8.5 Hz, 1H), 7.99 (dd, J = 8.5, 2.7 Hz, 1H), 8.53 (d, J = 2.7 Hz, 1H). Anal. Caled for C12H16CI2N2: C, 55.61; H, 6.22; N, 10.81. Found: C, 55.10; H, 6.36; N, 10.57.
EXAMPLE 6 Salt of 7a- (2-fluoro-3-pyridinyl) -hexahydro-1H-pyrrolizine hydrochloride
6a. 7a- (2-f luoro-3-pyridinyl) -hexah id ro-1 H-pyrrolizine A solution of nBuLi 2.5 M (680 μl, 1.7 mmol) in hexanes was added to diisopropylamine (220 μl, 1.7 mmol) in THF ( 4.5 ml) at room temperature. After 10 minutes of stirring, the reaction mixture was cooled to -78 ° C, pure 2-fluoropyridine was added and stirring was continued for 4 hours at -78 ° C. 1,2,3,5,6,7-hexahydropyrrolizinium perchlorate (500 mg, 2.4 mmol) was added and the reaction mixture was allowed to stir for 2 hours at -78 ° C, then was warmed to room temperature. A solution of 2N HCl was added, then the mixture was emptied over EtOAc. The phases were separated, and the aqueous phase was basified with 15% NaOH and extracted with CH2Cl2 (2X). The CH2Cl2 fractions were combined, dried (MgSO) and concentrated, and the residue was subjected to chromatography (silica gel; CHCl3 / MeOH, 98: 2) to give a clear oil (66 mg, 20%). Rf = 0.38 (CHCl3 / MeOH, 95: 5). MS (CI / NH3) m / e: 207 (M + H) +. H NMR (CDCl 3, 300 MHz) d 1.52-1.64 (m, 2H), 1.78-1.89 (m, 2H), 1.97-2.12 (m, 4H), 2.65-2.72 (m, 2H), 3.08-3.14 (m , 2H), 7.08-1.89 (m, 2H), 1.97-2.12 (m, 4H), 2.65-2.72 (m, 2H), 3.08-3.14 (m, 2H), 7.08-7.12 (m, 1H), 8.00 -8.03 (m, 1H), 8.18-8.24 (m, 1H).
6b. Salt of 7a- (2-fluoro-3-pyridinyl-hexahydro-1H-pyrrolizine hydrochloride
7a- (2-Fluoro-3-pyridinyl) -hexahydro-1H-pyrrolizine was dissolved (from step
6a, 59 mg, 0.3 mmol) in Et 2 O (8 ml), and Et 2 O saturated with HCl was added.
(g) The solvent was removed and the precipitate was recrystallized from MeOH / Et2O to give a white solid (54 mg, 77%). mp 185-186 ° C. MS
(CI / NH3) m / e: 207 (M + H) +. 1 H NMR (D 2 O, 300 MHz) d 2.06-2.21 (m, 2H),
2. 27-2.41 (m, 4H), 2.65-2.77 (m, 2H), 3.32-3.40 (m, 2H), 3.85-3.95 (m, 2H),
7. 47 (ddd, J = 7.7, 4.8, 1.8 Hz, 1H), 8.14 (ddd, J = 10.7, 7.7, 1.8 Hz, 1H),
8. 27 (ddd, J = 4.8, 1.8, 1.1 Hz, 1H). Anal. Caled for C 12 H 16 ClFN 2: C, 59.38; H, 6.64; N, 11.54. Found: C, 59.14; H, 6.53; N, 11.34.
Example 7 7a- (2-chloro-3-pyridinyl) -hexahydro-1 H-pyrrolizine hydrochloride
7a. 7a- (2-Chloro-3-pyridinyl) -hexahydro-1 H -pyrrolizine A solution of nBuLi 2.5 M (680 μL, 1.7 mmol) in hexanes was added to diisopropylamine (0.220 mL, 1.7 mol) in THF (4.5 mL) at room temperature. After 10 minutes of stirring, the reaction mixture was cooled to -78 ° C, pure 2-chloropyridine was added, and stirring was continued for 4 hours at -78 ° C. 1,2,3,5,6,7-Hexahydro-pyrrolizinium perchlorate (500 mg, 2.4 mmol) was added and the reaction mixture was allowed to stir for 2 hours at -78 ° C, and then heated to room temperature. A solution of 2N HCl was added, and the mixture was poured into EtOAc. The phases were separated, and the aqueous phase was basified with 15% NaOH and extracted with CH2Cl2 (2X). The CH2Cl2 fractions were combined, dried (MgSO4) and concentrated, and the residue was subjected to chromatography (silica gel; CHCl3 / MeOH, 100: 0 to 99.5: 0.5) to give a clear oil (18 mg, 5% ). Rf = 0.30 (CHCl3 / MeOH, 99: 1). MS (CI / m / e: 223 (M + H) +. 1 H NMR (CDCl 3, 300 MHz) d 1.50-1.61 (m, 2H), 1.78-1.89 (m, 2H), 2.10-2.29 (m, 4H), 2.69-2.75 (m, 2H), 3.04-3.11 (m , 2H), 7.17 (dd, J = 7.7, 4.8 Hz, 1H), 8.21 (dd, J = 4.8, 1.8 Hz, 1H), 8.36 (dd, J = 7.7, 1.8 Hz, 1H).
7b. 7a- (2-chloro-3-pyridinyl) -hexahydro-1 H -pyrrolizine hydrochloride salt 7a- (2-Chloro-3-pyridinyl) -hexahydro-1 H -pyrrolizine (21 mg,
0. 1 mmol) in Et2O (6 ml), and Et2O saturated with HCl (g) was added. The solvent was removed and the precipitate was triturated (3X) with Et2O to give a yellow solid (26 mg, quant.) Mp 186-188 ° C. MS (CI / NH3) m / e: 223 (M + H) +. 1 H NMR (D 2 O, 300 MHz) d 2.03-2.18 (m, 2 H), 2229-2.41 (m, 2 H), 2.54-2.64 (m, 2 H), 2.75-2.84 (m, 2 H), 3.41-2.51 (m , 2H), 2.93-4.02 (m, 2H), 7.57 (dd, J = 8.1, 4.7 Hz, 1H), 8.01 (dd, J = 8.1, 1.7 Hz, 1H), 8.42 (dd, J = 4.7, 1.7 Hz, 1H). Anal. Caled for C 12 H 16 Cl 2 N 2: C, 55.61; H, 6.22; N, 10.81. Found: C, 55.21; H, 6.25; N, 10.45.
Example 8 7a- (5,6-Dichloro-3-pyridinyl) -hexahydro-1 H-pyrrolizine hydrochloride
8a. 2,3-dichloro-5-iodopyridine 5-amino-2,3-dichloropyridine (15.0 g, 92.0 mmol, prepared according to V. Koch and S. Schnatterer, Synthesis, 1990, 499-501) was dissolved in DME ( 30 ml) and subjected to diazotization conditions according to the procedure of MP Doyle and WJ Bryker (Journal of Organic Chemistry, 1 979, 44, 1572). The dissolved pyridine analog was added to a solution of BF3 complex etherate (17 ml, 138 mmol) at -15 ° C. Then t-butyl nitrite in DME (92 ml) was added at a rate so that the temperature never rose from -5 ° C. After complete addition, the reaction mixture was allowed to warm to 5 ° C and was stirred an additional 45 minutes. Pentane was added and the resulting paste was filtered. The filter cake was washed with cold Et 2 O, and the solid was dried with air to give a light orange solid (22.3 g). A salt sample of crude diazonium tetrafluoroborate (5.1 g, 19.5 mmol) and Kl (3.5 g, 21.4 mmol) in CH3CN (1 30 mL) was combined and allowed to stir at room temperature for 1 8 hours. A 1 0% solution of Na 2 S 2 O 3 was carefully added, the biphasic mixture was poured over Et 2 O, and the phases were separated. The organic phase was dried (MgSO) and concentrated, and the residue was subjected to chromatography (silica gel; hexanes / CH2Cl2, 10: 1) to give a white solid (4.0 g, 75%). mp 55-57 ° C. Rf = 0.43 (hexanes / CH2Cl2, 2: 1). 1 H NMR (CDCl 3, 300 MHz) d 8.09 (d, J = 1.8 Hz, 1 H), 8.5 (d, J = 1.8 Hz, 1 H).
8b. 7a- (5,6-dichloro-3-pyridinyl) -hexahydro-1H-pyrrolizine A solution of 1.7 M tBuLi (4.7 ml, 8.0 mmol) enpentane was added to 2,3-dichloro-5-iodopyridine ( step 8a, 1.0 g, 3.65 mmol) in Et2O (15 ml) pre-cooled -100 ° C. After stirring for 2 minutes, 1, 2, 3,5,6,7-hexahydropyrrolizinium perchlorate (1.5 g, 7.3 mmol) was added and the reaction mixture was allowed to stir for 20 minutes at -100 ° C. C, and then gradually warm to -20 ° C. HCl 2N was added, and the ice bath was removed. After warming to room temperature, the reaction mixture was poured into EtOAc and the phases were separated. The aqueous phase was basified with 15% NaOH solution and extracted with CH2Cl2 (2X). The CH2Cl2 phases were combined, dried (MgSO4), concentrated and the residue chromatographed (silica gel; CHCl3 / MeOH, 99.5: 0.5) to give a light yellow oil (510 mg, 54%). MS (CI / NH3) m / e: 257 (M + H) +. 1 H NMR (CDCl 3, 300 MHz) d 1.59-1.71 (m, 2 H), 1.80-2.08 (m, 6 H), 2.64-2.72 (m, 2 H), 3.11-3.20 (m, 2 H), 7.99 (d, J = 2.2 Hz, 1H), 8.36 (d, J = 2.2 Hz, 1H).
8c. 7a- (5,6-Dichloro-3-pyridinyl) -hexahydro-1H-pyrrolizine hydrochloride salt. Paste 7a- (5,6-dichloro-3-pyridinyl) -hexahydro-1 H -pyrrolizine (from step 8b) , 128 mg, 0.50 mmol) in Et 2 O (8 ml), and Et 2 O saturated with HCl (g) was added. The solvent was removed, and the solid was recrystallized from MeOH / Et2O to give a white solid (111 mg, 75%). Mp 215-217 ° C. MS (CI / NH3) m / e: 257 (M + H) +. 1 H NMR (D 2 O, 300 MHz) d 2.12-2.50 (m, 6H), 2.54-2.65 (m, 2H), 3.35-3.43 (m, 2H), 3.79-3.88 (m, 2H), 8.21 (d, J = 2.4 Hz, 1H), 8.47 (d, J = 2.4 Hz, 1H). Anal. Caled for C 12 H 15 Cl 3 N 2: C, 49.09; H, 5.15; N, 9.54. Found: C, 49.01; H, 5.15; N, 9.44.
EXAMPLE 9 7a- (5-Pyrimidin-N-hexahydro-1 H -pyrrolizine 9a. 7a- (5-pi rim idyl) -hexah id ro-1 H-pyrrolizine hydrochloride A 1.7 M tBuLi solution was added ( 1.6 ml, 2.6 mmol) in pentane to 5-bromopyrimidine (190 mg, 1.2 mmol) in Et 2 O: THF (1: 1, 12 ml) at -100 ° C. After stirring for 10 minutes, perchlorate of 1 was added, 2,3,5,6,7-hexahydropyrrolizinium (500 mg, 2.4 mmol) was added to the reaction paste, and stirring was continued for 30 minutes, then the reaction mixture was allowed to warm to 0 ° C and stir for 1 hour, a 2N HCl solution was added, and the reaction mixture was poured into Et20 and the phases were separated.The aqueous phase was basified with 15% NaOH solution and extracted with CH2Cl2 (2X). of CH2Cl2 were combined, dried (MgSO4), concentrated and the residue was subjected to chromatography (silica gel; CHCl3 / MeOH, 98: 2) to give a clear oil (40 mg, 18%). NH 3) m / e: 190 (M + H) +. H NMR (CDCl 3, 30 0 MHz) d 1.60-1.73 (m, 2H), 1.82-2.11 (m, 6H), 2.66-2.75 (m, 2H), 3.15-3.21 (m, 2H), 8.85 (s, 2H), 9.05 (s) , 1 HOUR).
9b. 5- (7a-Hexahydro-1H-pyrrolizinyl) pyrimidine hydrochloride salt Paste 7a- (5-pyrimidinyl) -hexahydro-1 H -pyrrolizine (from step 9a, 33 mg, 0.2 mmol) in Et2O (7 ml) and saturated HCl was added with HCl (g). The solvent was removed to give a hygroscopic white solid (23 mg, 60%). MS (CI / NH3) m / e: 190 (M + H) +. 1 H NMR (D 2 O, 300 MHz) d 2.13-2.70 (m, 8 H), 3.38-3.46 (m, 2 H), 3.81-3.90 (m, 2 H), 8.99 (s, 2 H), 9.17 (s, 1 H). Anal. Caled for CnH ^ CINs-O.d HCl: C, 54.16; H, 6.82; N, 17.22. Found: C, 54.42; H, 7.26; N, 16.95.
Example 10 7a- (2,6-difluoro-3-pyridinyl) -hexahydro-1 H -pyrrolizine hydrochloride
10a. 7a- (2,6-difluoro-3-pyridinyl) -hexahydro-1H-pyrrolizine A solution of nBuLi 2.5 M (675 μl, 1.7 mmol) in hexanes was added to diisopropylamine (220 μl, 1.6 mmol) in THF (4.5 ml) at room temperature. After 10 minutes of stirring, the reaction mixture was cooled to -78 ° C, 2,6-difluoropyridine (145 μl, 1.6 mmol) was introduced and stirring was continued for 1 hour at -78 ° C. Then perchlorate 1, 2,3,5,6,7-hexahydropyrrolizinium (500 mg, 2.4 mmol) was added, and the cold bath was removed. After warming to room temperature, a 2N HCl solution was added and the phases were separated after the reaction mixture was poured into EtOAc. The aqueous phase was basified with 15% NaOH solution and extracted with CH2Cl2 (2X). The CH2Cl2 extracts were combined, dried (MgSO), concentrated and chromatographed (silica gel; CHCl3 / MeOH, 98: 2) to give a clear oil (180 mg, 50%). MS (CI / IMH3) m / e: 225 (M + H) +. 1 H NMR (CDCl 3, 300 MHz) d 1.5-1.63 (m, 2 H), 1.78-1.89 (m, 2 H), 1.92-2.10 (m, 4 H), 2.63-2.70 (m, 2 H), 3.08-3.12 (m , 2H), 6.72 (dd, J = 8.1, 3.0 Hz, 1H), 8.33 (dd, J = 18.0, 8.1 Hz, 1H).
10b. 7a- (2,6-difluoro-3-pyridinyl) -hexahydro-1H-pyrrolizine hydrochloride salt A solution of Et2O saturated with HCl (g) was added to 7a- (2,6-difluoro-3-pyridinyl) - hexahydro-1 H-pyrrolizine (from step 10a, 1 74 mg, 0.8 mmol) in Et 2 O (10 mL). The paste was filtered and the filter cake was washed with Et2O to give a white solid (1.38 mg, 68%). Mp 205-206 ° C. MS (CI / NH3) m / e: 225 (M + H) +. 1 H NMR (D 2 O, 300 MHz) d 2.08-2.21 (m, 2H), 2.26-2.40 (m, 4H), 2.64-2.73 (m, 2H), 3.31 -3.40 (m, 2H), 3.82-3.90 ( m, 2H), 7.14 (dd, J = 8.5, 2.7 Hz, 1 H), 8.22-8.30 (m, 1 H). Anal. Caled for C12H15CIF2N2: C, 54.92; H, 5.70; N, 10.52. Found: C, 55.28; H, 5.80; N, 10.74.
Example 1 1 Hydrochloride salt of 7α- (2,6-dichloro-3-pyridinyl) -hexahydro-1 H -pyrrolizine
1 1 a. 7a- (2,6-dichloro-3-pyridinyl) -hexah id ro-1 H-pyrrolizine A solution of nBuLi 2.5 M (675 μl, 1.7 mmol) in THF (4.5 ml) was added at room temperature. After stirring for 10 minutes, the reaction mixture was cooled to -78 ° C, 2,6-dichloropyridine (237 μl, 1-60 mmol) was added pure, and the stirring was continued for 1 hour at -78 ° C. . Perchlorate of 1, 2,3, 5,6,7-hexahydropyrrolizinium (550 mg, 2.40 mmol) was added and the reaction mixture was allowed to stir for 2 hours at -78 ° C, then was warmed to room temperature. A solution of 2N HCl was added and the mixture was emptied over EtOAc. The phases were separated and the aqueous phase was basified with 1% NaOH and extracted with CH2Cl2 (2X). The CH2Cl2 fractions were combined, dried (MgSO) and concentrated, and the residue was subjected to chromatography (silica gel; CHCl3 / MeOH, 98: 2) to give a clear oil (70.6 mg, 17%). MS (CI / NH3) m / e: 257/259 (M + H) +. 1 H NMR (CDCl 3, 300 MHz) d 1.47-1.61 (m, 2 H), 7.19 (d, J = 8.5 Hz, 1 H), 8.37 (d, J = 8.35 Hz, 1 H).
11b. 7a- (2,6-Dichloro-3-pyridinyl) -hexahydro-1 H -pyrrolizine hydrochloride salt 7a- (2,6-Dichloro-3-pyridinyl) -hexahydro-1 H -pyrrolizine (from step 11a) was dissolved , 62 mg, 0.24 mmol) in Et20, and Et2O saturated with HCl (g) was added. The solvent was removed, and the precipitate was triturated with Et2O to give a white solid (35.6 mg). mp 212-214 ° C.1H NMR (D2O, 300 MHz) d 2.02-2.18 (m, 2H), 2.28-2.41 (m, 2H), 2.52-2.64 (m, 2H), 2.72-2.83 (m, 2H ), 3.41-3.50 (m, 2H), 3.92-4.02 (m, 2H), 7.60 (d, J = 8.5 Hz, 1H), 8.00 (d, J = 8.5 Hz, 1H); MS (CI / NH3) m / e: 257/259 (M + H) +. Anal. Caled for C12H16CIFN2: C, 49.26; H, 4.82; N, 9.57. Found: C, 49.14; H, 5.03; N, 9.47.
EXAMPLE 12 Salt of 7a- (6-fluoro-3-pyridinyl) -hexahydro-1 H -pyrrolizine hydrochloride
12a. 2-fluoro-5-nitropyridine 2-chloro-5-nitropyridine (100 g, 0.656 mol, Aldrich), KF were combined
(84.1 g, 1448 mol), Ph4PBr (95.3 g, 0.227 mol) and acetonitrile (1.5 I) and heated to reflux until no starting material remained. The volume was reduced to 750 ml, and the mixture was diluted with 21 ether, filtered and concentrated. The residue was triturated with hot hexane (5 x 1 L). The hexane extracts were combined and concentrated to give 48 g, (54%).
1 H NM R (D 2 O, 300 MHz) d 7.15 (dd, J = 3, 6 Hz, 1 H), 8.64 (m, 1 H), 9.15 (d, J = 1.6 Hz, 1 H).
12b. 5-amino-2-fluoropyridine. 2-Fluoro-5-nitropyridine (52.35 g, 368 mmol, step
12a) with 5% Pd / C (1000 mg) in EtOH (100 ml) and the mixture was stirred under an atmosphere of H2 for 4 days. The mixture was filtered and concentrated, and the residue was subjected to chromatography (silica gel; EtOAc / hexane, 1: 9 to 1: 1) to give 30.9 g (75%) of the title compound: 1 H NMR (DMSO -d6, 300 MHz) d 6.74 (dd, J = 3, 6 Hz, 1 H), 7.1 1 (m, 1 H), 7.26 (t, J = 1 Hz, 1 H); MS (CI / NH 3) m / z: 1 1 3 (M + H) +, 1 30 (M + NH 4) +.
12c. 2-fluoro-5-vodopyridine 5-Amino-2-fluoropyridine (990 mg, 8.83 mmol, from step 12b) in DME (5 ml) was added dropwise to a solution of diethyl etherate boron trifluoride (1. 6 ml, 13.2 mmol) at -1 0 ° C. After stirring for 15 minutes, t-butyl nitrite in DME (1.5 ml) was carefully added to the reaction mixture, while keeping the temperature below -5 ° C. After complete addition, the temperature was allowed to gradually rise to 5 ° C over 1 hour. The solution was re-cooled to -10 ° C, the residue was triturated with pentane (2X) and Et2O, then all solvents were removed in vacuo. The crude diazonium tetrafluoroborate salt was dissolved in acetonitrile (50 ml), Kl (1.6 g, 9.7 mmol) was added and the mixture was stirred for 24 hours. A solution of 10% sodium thiosulfate was carefully added, the mixture was emptied over Et20 and the phases were separated. The organic phase was dried (MgSO 4) and concentrated, and the residue was subjected to chromatography (silica gel; EtOAc / hexane, 1:20) to give a white solid (1.2 g, 59%): 1 H NMR (CDCl 3, 300 MHz) d 6.79 (dd, J = 8.4, 2.6 Hz, 1H), 8.04 (ddd, J = 8.4, 7.4 2.6 Hz, 1H), 8.43 (dd, 2.6, 0.7 Hz, 1H).
12d. 7a- (6-fluoro-3-pyridinyl) -hexahydro-1 H -pyrrolizine 2-Fluoro-5-iodopyridine (200 μl, 0.90 mmol) was dissolved in Et 2 O and cooled to -78 ° C. A solution of t-BuLi 2.5 M (1.2 ml, 1.98 mmol) in pentane was added, and the reaction was stirred for 2 minutes. 1,2,3,5,6,7-hexahydropyrrolizinium perchlorate (375 mg, 1.80 mmol) was added, and the reaction mixture was allowed to stir for 10 minutes at -78 ° C, then allowed to warm at -20 ° C. The ice bath was removed, 2N HCl was added, and the mixture was extracted with Et2O. The phases were separated and the aqueous phase was basified with 15% NaOH and extracted with CH2Cl2 (2X). The CH2Cl2 fractions were combined, dried (MgSO) and concentrated, and the residue was subjected to chromatography (silica gel; CHCl3 / MeOH; 98: 2) to give a clear oil (75 mg, 40%). 1 H NMR (CDCl 3, 300 MHz) d 1.58-1.73 (m, 2H), 1.79-2.05 (m, 6H), 2.64-2.73 (m, 2H), 3.12-3.19 (m, 2H), 6.82 (dd, J = 8.4, 2.7 Hz, 1H), 7.90 (m, 1H), 8.30 (dd, J = 1.4, 0.7 Hz, 1H); MS (CI / NH3) m / z: 207 (M + H) +.
12e. 7a- (5-Fluoro-3-pyridinyl-hexahydro-1H-pyrrolizine hydrochloride salt) 7a- (5-Fluoro-3-pyridinyl) -hexahydro-1H-pyrrolizine (62 mg, 0.24 mmol, from step 12d) was dissolved. ) in Et2O, and Et2O saturated with HCl (g) was added.The solvent was removed and the precipitate was triturated to give a white solid (57.1 mg, 69%), mp 168-169 ° C.1H NMR (D2O, 300 MHz) d 2.13-2.50 (m, 6H), 2.58-2.67 (m, 2H), 3.34-3.42 (m, 2H), 3.78-3.87 (m, 2H), 7.24 (dd, J = 8.8, 2.4 Hz, 1H), 8.13 (ddd, J = 8.8, 7.2, 2.7 Hz, 1H), 8.36 (dd, J = 2.7, 1.4 Hz, 1H); MS (CI / NH3) m / z: 207 (M + H) + Anal Caled for C12H16CIFN2: C, 59.38; H, 6.64; N, 11.54 Found: C, 59.51; H, 6.52; N, 11.30.
EXAMPLE 13 7α- (3-Ethyl-5-isoxazolyl) -hexahydro-1H-pyrrolizine hydrochloride salt
13a. 7a-ethynyl-hexahydro-1 H-pyrrolizine 1, 2,3,5,6,7-hexahydropyrrolizinyl perchlorate (1.0 g, 4.8 mmol) was added to a solution of ethynylmagnesium bromide 0.5M (29 ml, 14.3 mmol) in THF at room temperature. The reaction mixture was allowed to stir for 45 minutes, and 15% NaOH was added. The paste was diluted with brine: water (1: 1) and extracted with CH2Cl2 (3X). The organic phases were combined, dried (MgSO4), concentrated and subjected to chromatography (silica gel; CHCl3 / MeOH, 90:10), to give an amber oil (463 mg, 71%): 1H NMR (CDCl3, 300 MHz ) d 1.75-2.06 (m, 6H), 2.14-2.23 (m, 2H), 2.33 (s, 1H), 2.53-2.62 (m, 2H), 3.22-3.28 (m, 2H); MS (CI / NH3) m / z: 136 (M + H) +.
13b. 7a- (3-et i l-5-isoxazole i Q-hexah id ro-1 H-pyrrolizine Nitropropane (0.475 ml, 5.29 mmol) and phenylisocyanate (1.0 ml, 9.5 mmol) were dissolved in benzene (10 ml) and They were added to a flask containing 7a-ethynyl-hexahydro-1H-pyrrolizine (358 mg, 2.65 mmol, from step 13a) .The solution was stirred at room temperature for 1 hour and refluxed for 5 hours.The mixture was cooled, filtered, concentrated and diluted with EtOAc The solution was extracted with 6N HCl The aqueous phase was made basic with 15% NaOH and extracted with methylene chloride The organic extracts were combined, dried (MgSO 4) and concentrated. chromatography (silica gel; CHCl 3 / MeOH, 98: 2) to give an amber oil (274 mg, 50%). 1 H NMR (CDCl 3, 300 MHz) d 1.25 (t, J = 7.5 Hz, 3 H), 1.75- 1.92 (m, 6H), 2.15-2.25 (m, 2H), 2.60-2.69 (m, 4H), 3.13-3.20 (m, 2H), 5.98 (s, 1H); MS (CI / NH3) m / z : 207 (M + H) +.
13c. 7a- (3-ethyl-5-oxazole P-hexahydro-1H-pyrrolizine hydrochloride salt) 7a- (3-ethyl-5-isoxazolyl) -hexahydro-1H-pyrrolizine (265 mg,
1. 30 mmol, from step 13b) in Et 2 O, and Et 2 O saturated with HCl (g) was added. The solvent was removed and the precipitate was recrystallized from methanol / ethanol to give the title compound as a white solid: mp 139-140 ° C; 1 H NMR (D 2 O, 300 MHz) d 1.23 (t, J = 7.5 Hz, 3 H), 2.17-2.40 (m, 6 H), 2.58-2.75 (m, 4 H), 3.29-3.38 (m, 2 H), 3.69- 3.77 (m, 2H), 6.64 (s, 1H), MS (CI / NH3) m / z: 207 (M + H) +; Anal. Caled for C? 2H18N2O »HCl: C, 59.38; H, 7.89; N, 11.54. Found: C, 59.44; H, 7.94; N, 11.48.
EXAMPLE 14 7a- (3-Propyl-5-oxazole-OH-hexahydro-1H-pyrrolizine-14a-7a- (3-propyl-5-isoxazolyl) -hexahydro-1H-pyrrolizine hydrochloride salt) Nitrobutane (0.705 ml, 6.66 mmol) and phenylisocyanate (1.50 ml, 13.3 mmol) in benzene (13.5 ml) were added to a flask containing 7a-ethynyl-hexahydro-1H-pyrrolizine (450 mg, 3.33 mmol, from step 13a). At room temperature for 1 hour and reflux for 5 hours, the mixture was cooled, filtered, concentrated and diluted with EtOAc, the solution was extracted with 6N HCl, the aqueous phase was made basic with 15% NaOH and extracted with sodium chloride. The organic extracts were combined, dried (MgSO4) and concentrated, the residue was subjected to chromatography (silica gel, CHCl3 / MeOH, 98: 2) to give an amber oil (392 mg, 53%). CDCI3, 300 MHz) d 0.97 (t, J = 7.5 Hz, 3H), 1.61-1.92 (m, 8H), 2.15-2.26 (m, 2H), 2.55-2.69 (m, 4H), 3.13-3.20 (m , 2H), 5.96 (s, 1H), MS (CI / NH3) m / z: 221 (M + H) +.
14b. 7a- (3-Propyl-5-isoxazolyl) -hexahydro-1H-pyrrolizine hydrochloride salt 7a- (3-propyl-5-isoxazolyl) -hexahydro-1H-pyrrolizine (265 mg, 1.30 mmol, from step 14a) was dissolved ) in Et2O, and Et2O saturated with HCl (g) was added. The solvent was removed and the precipitate was triturated with Et 2 O and dried to give the title compound as a free flowing white powder, mp 97-98 ° C. MS (NH3 / CI) m / z: 207 (M + H) +; 1 H NMR (D 2 O, 300 MHz) d 0.92 (t, J = 7.5 Hz, 3 H), 1.63-1.75 (m, 2 H), 2.20-2.40 (m, 6 H), 2.59-2.71 (m, 4 H), 3.30- 3.38 (m, 2H), 3.70-3.78 (m, 2H), 6.65 (s, 1H); MS (CI / NH3) m / z: 221 (M + H) +. Anal. Caled for C1 3H20N2O »HCl: C, 59.38; H, 7.89; N, 1 1 .54. Found: C, 59.44; H, 7.94; N, 1 1 .48.
Example 1 5 Hydrochloride salt of 7a- (3-benzyl-5-isoxazolyl) -hexahydro-1 H -pyrrolizine
15a. 2-phenylnitroetene Benzaldehyde (1.0 g, 94.2 mmol) and nitromethane (5.1 mL, 94.2 mmol) were dissolved in MeOH, the solution was cooled to -1 8 ° C, and NaOH (3.9 g, 98.9 mmol) in solution was added. aqueous (80 ml) while maintaining the temperature below -1 0 ° C. The mixture was stirred at 0 ° C for 2 hours, then stored at 5 ° C overnight. The solution was then emptied into stirred acid (200 ml of conc HCl / 300 ml of H2O). The precipitate was collected, washed and recrystallized from EtOH to give the title compound as light orange needles (5.15 g, 37%).
15b. 2-phenylnitroethane 2-phenylnitroethene (5.12 g, 34.3 mmol, from step 1 5a) was dissolved in CHCl3 / i-PrOH (41 0:85 ml) and SiO2 (51.4 g) was added. NaBH 4 (5.2 g, 1 37 mmol) was added in portions, and the mixture was stirred for 90 minutes at room temperature. HCl (0.5 N, 100 ml) was added and the mixture was stirred for 30 minutes. The layers were separated and the aqueous phase was extracted with methylene chloride. The organic layers were combined, dried (MgSO4) and concentrated. The residue was chromatographed on silica gel (levigando with ether 1: 30) to give the title compound as an oil (3.89 g, 75%).
15c. 7a- (3-benzyl-5-isoxazol-yl) -hexah id ro-1 H-pyrrolizine 2-phenylnitroethane (895 mg, 5.92 mmol, from step 15b) and phenylisocyanate (1.3 ml, 11.8 mmol) were dissolved in benzene (12 ml) and added to a flask containing 7a-ethynyl-hexahydro-1 H-pyrrolizine (400 mg, 2.96 mmol, from step 13a). The solution was stirred under reflux for 5 hours, cooled and stirred for 48 hours at room temperature. The mixture was filtered and extracted with 6 N HCl. The aqueous phase was made basic with 15% NaOH and extracted with methylene chloride. The organic extracts were combined, dried (MgSO4) and concentrated. The residue was subjected to chromatography (silica gel; CHCl3 / MeOH, 99: 1) to give an amber oil (415 mg, 52%). H NMR (CDCl 3, 300 MHz) d 1.71-1.92 (m, 6H), 2.11-2.23 (m, 2H), 2.58-2.66 (m, 2H), 3.08-3.15 (m, 2H), 3.95 (s, 2H) ), 5.87 (s, 1H), 7.20-7.34 (m, 5H); MS (CI / NH3) m / z: 269 (M + H) +.
15d. 7a- (3-Benzyl-5-isoxazolyl) -hexahydro-1 H -pyrrolizine hydrochloride salt 7a- (3-benzyl-5-isoxazolyl) -hexahydro-1H-pyrrolizine (407 mg, 1.52 mmol, from step 15c) in Et2O, and Et2O saturated with HCl (g) was added. The solvent was removed and the precipitate was recrystallized from MeOH and dried to give the title compound as white needles: mp 126-127 ° C; 1 H NMR (D 2 O, 300 MHz) d 2.17-2.36 (m, 6 H), 2.53-2.62 (m, 2 H), 3.28-3.36 (m, 2 H), 3.67-3.75 (m, 2 H), 4.08 (s, 2 H) ), 6.57 (s, 1H), 7.34-7.45 (m, 5H); MS (CI / NH3) m / z: 269 (M + H) +; Anal. Caled for C17H20N2O «HCI: C, 66.99; H, 6.94; N, 9.19. Found: C, 66.99; H, 6.87; N, 9.09.
Example 16 Salt of 7a- (3-hydroxy-5-pyridinyl) -hexahydro-1 H -pyrrolizine hydrochloride
16a. 3-benzyloxy-5-bromopyridine Sodium hydride (60% in mineral oil, 40.9 g, 1.0 mole) was cooled in DMF (800 ml) at 0 ° C, and benzyl alcohol was added slowly (105 ml, 1. 0 mol). After stirring for 1 hour at room temperature, 3, 5-dibromopyridine (200.4 g, 846 mmol) was added and the mixture was allowed to stir for 16 hours. The saturated N HCl solution (500 ml) was added followed by water (400 ml), and the mixture was extracted with Et 2 O (5 x 300 ml). The combined Et2O extracts were washed with 50% brine (6x300 ml), dried (MgSO4), concentrated and the residue was crystallized from Et2O to give a white solid (161 g, 72%): 1 H NMR (CDCl 3, 300 MHz) d 5.1 0 (s, 2H), 7.50-7.35 (m, 6H), 8.37-8.27 (m, 2H); MS (CI / NH3) m / z: 264/266 (M + H) +.
16b. 7a- (3-benzyloxy-5-pyridi ni l) -hexahydro-1 H -pyrrolizine 3-Benzyloxy-5-bromopyridine (1.1 g, 4.47 mmol) was dissolved in Et 2 O and cooled to -78 ° C. A solution of t-BuLi 2.5 M (5.8 μl, 9.83 mmol) in pentane was added., and the reaction was stirred for 10 minutes. 1, 2,3,5,6,7-hexahydropyrrolizinium perchlorate (1.4 g, 6.70 mmol) was added and the reaction mixture was allowed to stir for 3 hours at -78 ° C, then allowed to settle. warm to -20 ° C and stir for 2 hours. The cold bath was removed, 2N HCl was added, and the mixture was extracted with Et2O. The phases were separated and the aqueous phase was basified with 15% NaOH and extracted with CH2Cl2 (2X). The CH2Cl2 fractions were combined, dried (MgSO4) and concentrated, and the residue was subjected to chromatography (silica gel; CHCl3 / MeOH, 98: 2) to give a clear oil (286 mg, 22%): mp 45-49 ° C. 1 H NMR (CDCl 3, 300 MHz) d 1.58-1.69 (m, 2 H), 1.78-1.83 (m, 2 H), 1.89-2.03 (m, 4 H), 2.63-2.72 (m, 2 H), 3.05-3.18 (m , 2H), 5.12 (s, 2H), 7.31-7.54 (m, 6H), 8.17 (d, J = 3.0 Hz, 1H), 8.29 (d, J = 1.7 Hz, 1H); MS (CI / NH3) m / z: 295 (M + H) +.
16c. 7a- (3-h-idroxy-5-pyridinyl) -hexah id ro-1 H-pyrrolizine 7a- (3-benzyloxy-5-pyridinyl) -hexahydro-1H-pyrrolizine (260 mg, 0.88 mmol, from step 16b) was dissolved. ) in methanol (9 ml), 10% Pt / C (35 mg) was added and the mixture was stirred under 1 atm of H2 for 16 hours. The catalyst was removed, the filtrate was concentrated and the residue was subjected to chromatography (silica gel; CHCl3 / MeOH) 0.5% NH4OH, 90: 10: 0 to 90: 10: 0.5) to give the title compound as a solid. white (114 mg, 63%). 1 H NMR (D 2 O, 300 MHz) d 2.07-2.40 (m, 6H), 2.49-2.58 (m, 2H), 3.26-3.34 (m, 2H), 3.71-3.80 (m, 2H), 7.00 (dd, J = 2.4, 2.0 Hz, 1H), 7.80 (d, J = 2.0 Hz, 1H), 7.85 (d, J = 2.4 Hz, 1H); MS (CI / NH3) m / z: 205 (M + H) +.
16d. 7a- (3-Hydroxy-5-pyridinyl) -hexahydro-1H-pyrrolizine hydrochloride salt 7a- (3-hydroxy-5-pyridinyl) -hexahydro-1 H -pyrrolizine (150 mg, 0.56 mmol, step 16c) in methylene chloride, and Et2O saturated with HCl (g) was added. The solvent was removed, and the solid was dried to give the title compound as a white powder (114 mg, 91%): mp 175-180 ° C (dec); 1 H NMR (D 2 O, 300 MHz) d 2.11-2.63 (m, 8 H), 3.35-3.44 (m, 2 H), 3.80-3.89 (m, 2 H), 7.66 (dd, J = 2.4, 2.0 Hz, 1 H), 8.23 (d, J = 2.4 Hz, 1H), 8.29 (d, J = 2.0 Hz, 1H); MS (CI / NH3) m / z: 205 (M + H) +. Anal. Caled for C12H16N2O «HCI: C, 53.40; H, 6.65; N, 10.38. Found: C, 53.55; H, 6.62; N, 10.24.
Example 17 Salt of 7a- (5-bromo-3-pyridinyl) -hexahydro-1H-pyrrolizine hydrochloride
17a. 7a- (5-bromo-3-pyrid i ni l) -hexahydro-1 H -pyrrolizine 3,5-Dibromopyridine (500 mg, 2.11 mmol, Aldrich) was dissolved in Et 2 O and cooled to -95 ° C. A solution of 2.5 M t-BuLi (1.7 M in pentane, 2.7 ml, 4.64 mmol) in pentane was added dropwise. 1, 2,3,5,6,7-hexahydropyrrolizinium perchlorate (663 mg, 3.2 mmol) was added and the reaction mixture was allowed to stir and warm to -10 ° C and stir for 2 hours. The cold bath was basified with 15% NaOH and extracted with CH2Cl2 (2X). The CH2Cl2 fractions were combined, dried (MgSO4) and concentrated, and the residue was subjected to chromatography (silica gel; CHCl3 / MeOH, 98: 2) to give a clear oil (160 mg, 28%): 1H NMR ( CDCI3, 300 MHz) d 1.57-1.71 (m, 2H), 1.79-2.04 (m, 6H), 2.62-2.73 (m, 2H), 3.11-3.20 (m, 2H), 8.04 (dd, J = 2.0, 2.0 Hz, 1H), 8.46 (d, J = 2.0 Hz, 1H), 8.58 (d, J = 2.0 Hz, 1H); MS (Ci / NH3) m / z: 267/269 (M + H) +.
17b. 7a- (5-bromo-3-pyridyl-hexahydro-1H-pyrrolizine hydrochloride salt) 7a- (5-bromo-3-pyridinyl) -hexahydro-1H-pyrrolizine (107 mg,
0. 52 mmol, from step 16c) in methylene chloride, and Et2O saturated with HCl (g) was added. The solvent was removed and the solid was crystallized from MeOH / Et2O and dried to give the title compound as an off-white powder (118 mg). mp 192-194 ° C. 1 H NMR (D 2 O, 300 MHz) d 2.13-2.51 (m, 6H), 2.57-2.66 (m, 2H), 3.36-3.44 (m, 2H), 3.81-3.89 (m, 2H), 8.22 (s, 1H ), 8.65 (s, 1H), 8.72 (s, 1H); MS (CI / NH3) m / z: 267/269 (M + H) +. Anal. Caled for C12H15BrN2 «HCI: c, 47.47; H, 5.31; N, 99.23. Found: C, 47.40; H, 5.22; N, 8.98.
EXAMPLE 18 Salt of 7a- (6-fluoro-5-methyl-3-pyridinyl) -hexahydro-1H-pyrrolizine hydrochloride
18. 2-fluoro-3-methyl-5-nitropyridine 2-Chloro-3-methyl-5-nitropyridine (15 g, 86.9 mmol;
Maybridge Chemical Co.), KF (12 g, 258 mmol) and tetraphenylphosphonium bromide (20 g, 47.7 mmol; Aldrich) in 200 ml of acetonitrile and heated at reflux for 4 days. The mixture was diluted with Et2O (500 mL) and filtered, and the filtrate was concentrated. The residue was triturated with hot hexane (4 x 200 ml), and the hexane solutions were combined and concentrated to give the title compound as a solid (8.4 g, 60%); 1 H NMR (DMSO-d 6, 300 MHz) d 2.42 (s, 3 H), 8.43 (m, 1 H), 8.95 (dd, J = 1.6 Hz, 1 H); MS (CI / NH3) m / z: 57 (M + H) +.
1 8b. 5-amino-2-fluoro-3-methyl pyridine. 2-Fluoro-3-methyl-5-nitropyridine (8.2 g, mmol) was combined with 5% Pd / C (100 mg) in EtOH (100 ml) under one atmosphere. of H2 for 16 hours. The mixture was filtered and concentrated, and the crude product was subjected to chromatography (silica gel; CHCl3 / MeOH 99: 1 to 96.4) to give a solid (5.2 g, 78%): 1 H NMR (DMSO-d6, 300 M Hz) d 2.1 0 (s, 3H), 5.1 1 (brs, 2H), 6.95 (dd, J = 8.14 Hz, 1 H), 7.26 (t, J = 2.72 Hz, 1 H); MS (CI / NH3) m / z: 127 (M + H) +, 144 (M + NH4) +.
18c. 2-Fluoro-5-iodo-3-methylpyridine 5-Amino-2-fluoro-3-methylpyridine (397 mg, 3.1 mmol) in DME (1.7 mL) was added dropwise to a solution of diethyl etherate of Boron trifluoride (5.8 μl, 4.6 mmol) in DME (6 ml) at -1 7 ° C. After stirring for 1 5 min, neat t-butyl nitrite (442 μl, 3.7 mmol) was carefully added to the reaction mixture, while maintaining the temperature below -5 ° C. After complete addition, the temperature was allowed to gradually rise to 5 ° C over 1 h. After re-cooling to -1 7 ° C, pentane was added and then decanted. The light orange solid was triturated with pentane (2X) and Et2O (2X) and then the solvent was removed via positive N2 pressure to give a light orange solid. The curd diazonium tetrafluoroborate salt was dissolved in acetonitrile (6 ml) and Kl (570 mg, 3.4 mmol) was added at -10 ° C. The reaction was allowed to warm gradually to room temperature and was stirred overnight. A solution of 10% sodium thiosulfate was carefully added to the reaction mixture, which was then poured onto Et2O and the phases were separated. The organic phase was dried (MgSO4), concentrated and the residue was subjected to chromatography (silica gel; EtOAc / hexane, 1:50) to give a white solid (500 mg, 68%): 1H NMR (DMSO-de , 300 MHz) d 2.21 (s, 3H), 8.21 (m, 1H), 8.27 (m, 1H).
18d. 7a- (6-fluoro-5-methyl-3-pyridinyl ') -hexahydro-1 H -pyrrolizine 2-Fluoro-5-iodo-3-methylpyridine (200 mg, 0.84 mmol) was dissolved in Et 2 O and cooled at -95 ° C. A solution of 2.5 M t-BuLi (1.7 M in pentane, 1.1 ml, 1.80 mmol) in pentane was added dropwise. 1, 2,3,5,6,7-hexahydropyrrolizinium perchlorate (265 mg, 1.26 mmol) was added, and the reaction mixture was allowed to warm to -10 ° C with stirring for 2 hours. The cold bath was removed, 2N HCl was added, and the phases were separated. The aqueous phase was basified with 15% NaOH and extracted with CH2Cl2 (2X). The CH2Cl2 fractions were combined, dried (MgSO4) and concentrated, and the residue was subjected to chromatography (silica gel; CHCl3 / MeOH, 99: 1) to give the title compound as an oil (123 mg, 67%). . 1 H NMR (CDCl 3, 300 MHz) d 1.55-1.71 (m, 2 H), 1.78-2.04 (m, 6 H), 2.26 (s, 3 H), 2.64-2.72 (m, 2 H), 3.11-3.18 (m, 2 H) ), 7.70 (m, 1H), 8.09 (m, 1H); MS (CI / NH3) m / z: 221 (M + H) +.
18e. 7a- (6-Fluoro-5-methyl-3-pyridinyl) -hexahydro-1 H -pyrrolizine hydrochloride salt 7a- (6-fluoro-5-methyl-3-pyridinyl) -hexahydro-1 H -pyrrolizine was dissolved > (15 mg, 0.52 mmol, from step 18d) in Et 2 O, and Et 2 O saturated with HCl (g) was added. The solvent was removed, and the solid crystallized from
MeOH / Et 2 O and dried to give the title compound (white needles, 92 mg, 60%): mp 170-171 ° C; 1 H NMR (D 2 O, 300 MHz) d 2.12-2.47 (m, 9H),
2. 56-2.66 (m, 2H), 3.32-3.41 (m, 2H), 3.77-3.86 (m, 2H), 7.94 (m, 1 H), 8.14
(m, 1 H); MS (CI / NH3) m / z: 221 (M + H) +; MS (CI / NH3): m / z 221 (M + H +). Anal. Caled for C13H17FN2 »HCI: C, 60.82; H, 7.07; N, 1 0.91. Found:
C, 60.83; H, 6.80; N, 1 0.63.
Example 1 9 Hydrochloride salt of 7a- (6-chloro-5-methyl-3-pyridinyl) -hexahydro-1H-pyrrolizine
1 9a. 5-am i non-2-chloro-3-methyl pyridine 2-Chloro-3-methyl-5-nitropyridine (15 g, 86.9 mmol, from Maybridge Chemical Co.) was dissolved in a solution of H 2 O / AcOH (5%). : 1, 60 ml). Iron powder was added to the reaction mixture while maintaining the temperature below 40 ° C, and the mixture was stirred for 5 hours. The mixture was filtered through celite and the aqueous filtrate was extracted with EtOAc (4X). The filter cake was washed with EtOAc, and the EtOAc solutions were combined, dried (MgSO4), concentrated and chromatographed (silica gel; CHCl3 / MeOH, 98: 2) to give an orange solid (2.3 g, 89%): 1 H NMR (CD3OD, 300 MHz) d 2.25 (s, 3 H), 7.01 (d, J = 2.0 Hz, 1 H), 7.58 (d, J = 2.0 Hz, 1 H); MS (CI / NH3) m / z: 243/245 (M + H) +.
1 9b. 2-chloro-5-iodo-3-methyl pyridine 5-amino-2-chloro-3-methylpyridine (2.3 g) was added in the form of drops., 16.3 mmol) in DME (9.0 mL) was added to a solution of boron trifluoride diethyl etherate (3.0 mL, 24.4 mmol) in DME (30.5 mL) at -1 7 ° C. After stirring for 1 5 min, t-butyl nitrite (442 μL, 3.7 mmol) in DME (30.5 mL) was carefully added to the reaction mixture while maintaining the temperature below -5 ° C. After complete addition, the temperature was allowed to gradually warm to 5 ° C over 1 h. The mixture was re-cooled to -1 7 ° C, pentane was added and then decanted. The solid was triturated with pentane (3X) and Et2O (3X) and then the solvent was removed via positive N2 pressure. The crude diazonium tetrafluoroborate salt was dissolved in acetonitrile (15 ml) and Kl (3.0 g, 7.9 mmol) was added at -1 0 ° C. The reaction was allowed to warm gradually to room temperature and stir overnight. A solution of 10% sodium thiosulfate) was carefully added to the reaction mixture, which was then poured over Et2O and the phases were separated. The organic phase was dried (MgSO 4), concentrated and the residue was subjected to chromatography (silica gel; EtOAc / hexane, 1:50) to give a white solid (3.42 g, 83%): 1 H NMR (CD3OD, 300 MHz) d 2.34 (s, 3 H), 8.09 (d, J = 2.2 Hz, 1 H) , 8.42 (d, J = 2.2 Hz, 1 H).
19c. 7a- (6-Cl or ro-5-methyl-3-pyridinyl) -hexah id ro-1 H-pyrrolizine 2-Chloro-5-iodo-3-methylpyridine (1.0 g, 3.94 mmol) was dissolved in Et 2 O and it was cooled to -95 ° C. A solution of 2.5 M t-BuLi (1.7 M in pentane, 5.1 ml, 7.67 mmol) in pentane was added dropwise. 1,2,3,5,6,7-hexahydropyrrolizinium perchlorate (1.2 g, 5.92 mmol) was added and the reaction mixture was allowed to warm to -10 ° C with stirring for 2 hours. The cold bath was removed, 2N HCl was added, and the phases were separated. The aqueous phase was basified with 15% NaOH and extracted with CH2Cl2 (2X). The CH2Cl2 fractions were combined, dried (MgSO4) and concentrated, and the residue was subjected to chromatography (silica gel; CHCl3 / MeOH, 99: 1) to give the title compound (694 mg, 74%): -33 ° C; 1 H NMR (CDCl 3, 300 MHz) d 1.56-1.70 (m, 2 H), 1.78-2.05 (m, 6 H), 2.36 (s, 3 H), 2.64-2.72 (m, 2 H), 3.11-3.18 (m, 2 H) ), 7.67 (d, J = 2.0 Hz, 1H), 8.29 (d, J = 2.0 Hz, 1H); MS (CI / NH3) m / z: 237/239 (M + H) +.
19d. 7a- (6-Chloro-5-methyl-3-pyridinyl) -hexahydro-1H-pyrrolizine hydrochloride salt 7a- (6-chloro-5-methyl-3-pyridinyl) -hexahydro-1 H -pyrrolizine was dissolved ( 245 mg, 1.03 mmol) in Et 2 O, and Et 2 O saturated with HCl (g) was added. The solvent was removed and the solid was recrystallized from MeOH / Et2O and dried to give the title compound as white plates: mp 179-18 ° C; 1 H NMR (D 2 O, 300 MHz) d 2.14-2.48 (m, 9H), 2.56-2.65 (m, 2H), 3.34-3.42 (m, 2H), 3.79-3.87 (m, 2H), 7.89 (d, J = 3.0 Hz, 1H), 8.33 (d, J = 3.0 Hz, 1H); MS (CI / NH3) m / z: 237/239 (M + H) +; MS (CI / NH3): m / z 237 (M + H +). Anal.
Caled for C1 3H17CIN2 »HCl: C, 55.67; H, 6.54; N, 9.99. Found: C, 55.90; H, 6.57; N, 9.76.
EXAMPLE 20 7α- (6-Methyl-3-pyridinyl) -hexahydro-1 H-pyrrolizine hydrochloride salt
a. 5-amino-2-methylpyridine. 2-Methyl-5-nitropyridine (1.4 g, 10 mmol) and 1.0% Pd / C (200 mg) in MeOH (40 ml) were combined and allowed to stir under a H2 atmosphere for 1 8 hours. The reaction mixture was filtered through celite and the filtrate was concentrated. The residue was subjected to chromatography (silica gel; CHCl3 / MeOH, 95: 5) to give the title compound (845 mg, 77%): H NMR (CD3OD, 300 MHz) d 2.35 (s, 3H), 6.97 -7.06 (m, 2H), 7.85 (d, J = 2.5 Hz, 1 H).
20b. 5-iodo-2-methylpyridine 5-Amino-2-methylpyridine (825 mg, 7.6 mmol) in DME (4.0 ml) was added dropwise to a solution of boron trifluoride diethyl etherate (1.4 ml, 1 ml). 1.4 mmol) in DME (14.5 ml) at -17 ° C. After stirring for 1 5 min, t-butyl nitrite (1.1 ml, 9.2 mmol) in DME (14.5 ml) was carefully added to the reaction mixture while maintaining the temperature below -5 ° C. . After complete addition, the temperature was allowed to gradually rise to 5 ° C over 1 h. After re-refluxing at -1 7 ° C, pentane was added and then decanted. The solid was triturated with pentane (2X) and Et2O (2X) and then the solvent was removed via positive N2 pressure. The crude diazonium tetrafluoroborate salt was dissolved in acetonitrile (15 ml) and Kl (1.4 g, 8.4 mmol) was added at -10 ° C. The reaction was allowed to warm gradually to room temperature and stir overnight. A solution of 10% sodium thiosulfate was carefully added to the reaction mixture, which was then poured onto Et2O and the phases were separated. The organic phase was dried (MgSO4), concentrated and the residue was subjected to chromatography (silica gel; EtOAc / hexane, 1: 1 5) to give a pale white solid (31 5 mg, 83%): 1 H NMR (CDCl 3, 300 MHz) d 250 (s, 3 H), 6.97 (d, J = 8.1 Hz, 1 H), 7.86 (d, J = 8.1, 2.0 Hz, 1 H), 8.70 (d, J = 2.0 Hz , 1 HOUR); MS (CI / N H3) m / z: 220 (M + H) +.
20c. 7a- (6-methyl-3-pyridinyl) -hexahydro-1 H -pyrrolizine 5-iodo-2-methylpyridine (345 mg, 1.39 mmol) was dissolved in Et 2 O and cooled to -95 ° C. A solution of 2.5 M t-BuLi (1.7 M in pentane, 1.8 ml, 3.06 mmol) in pentane was added dropwise. 1, 2,3,5,6,7-hexahydropyrrolizinium perchlorate (435 mg, 2.1 mmol) was added and the reaction mixture was allowed to warm to -1 0 ° C with stirring for 2 hours. The cold bath was removed, 2N HCl was added, and the phases were separated. The aqueous phase was basified with 1% NaOH and extracted with CH2Cl2 (2X). The CH2Cl2 fractions were combined, dried (MgSO4) and concentrated, and the residue was subjected to chromatography (silica gel; CHCl 3 / MeOH, 95: 5) to give the title compound as an oil (126 mg, 45%): 1 H NMR (CDCl 3, 300 MHz) d 1.57-1.71 (m, 2H), 1. 77-2.05 (m, 6H), 2.52 (s, 3H), 2.64-2.72 (m, 2H), 3.12-3.19 (m, 2H), 7.05 (d, J = 8.1 Hz, 1H), 7.71 (dd, J = 8.1, 2.6 Hz, 1H), 8.56 (d, J = 2.6 Hz, 1H); MS (CI / NH3) m / z: 203 (M + H) +.
20d. 7a- (6-Methyl-3-pyridinyl) -hexahydro-1H-pyrrolizine dihydrochloride salt 7a- (6-Methyl-3-pyridinyl) -hexahydro-1H-pyrrolizine (115 mg, 0.57 mmol) was dissolved in Et2O, and Et2O saturated with HCl (g) was added. The solvent was removed, and the solid was crystallized from MeOH / Et2O and dried to give the title compound as a free flowing white powder: mp 205-208 ° C; 1 H NMR (D 2 O, 300 MHz) d 2.14-2.49 (m, 6H), 2.57-2.66 (m, 5H), 3.34-3.42 (m, 2H), 3.78-3.87 (m, 2H), 7.56 (d, J = 8.1 Hz, 1H), 8.05 (dd, J = 8.1, 2.7 Hz, 1H), 8.61 (d, J = 2.7 Hz, 1H); MS (CI / NH3) m / z: 203 (M + H) +; MS (CI / NH3): m / z 203 (M + H +). Anal. Caled for C13H18N2-2 HCμ? .8 H2O: C, 53.91; H, 7.52; N, 9.67. Found: C, 53.80; H, 7.46; N, 9.68.
Example 21 Salt of 7a- (5-methyl-3-pyridinyl) -hexahydro-1 H -pyrrolizine hydrochloride
21a.7a- (5-methyl-3-pyridinyl) -hexahydro-1H-pyrrolizine 7a- (6-chloro-5-methyl-3-pipdinyl) -hexahydro-1H-pyrrolizine (274 mg, 1.16 mmol, of Example 19c) and LAH (1.0 M in THF, 1.2 ml, 1.16 mmol) in THF (4.5 ml) and the mixture was stirred at room temperature for 4 hours. An additional amount of LAH (1.0 M in THF, 1.2 mL, 1.16 mmol) was added and the mixture was stirred overnight. An additional amount of LAH (2 equivalents) was added, and the reaction was stirred at room temperature for 24 hours and at 80 ° C for 5 hours. The reaction was quenched with 10% K2CO3 solution), and the resulting paste was filtered. The filtrate was diluted with EtOAc and 15% NaOH, and the phases were separated. The aqueous phase was extracted with methylene chloride, and all the organic solutions were combined, dried and concentrated. The residue was subjected to chromatography (silica gel; CHCl 3 / MeOH, 98: 2) to give the title compound as an oil (116 mg, 49%): 1 H NMR (CDCl 3, 300 MHz) d 1.57-1.71 (m , 2H), 1.77-2.06 (m, 6H), 2.32 (s, 3H), 2.66-2.74 (m, 2H), 3.12-3.19 (m, 2H), 7.63 (s, 1H), 8.24 (s, 1H) ), 8.50 (s, 1H); MS (CI / NH3) m / z: 203 (M + H) +.
21b. Salt of 7a- (5-methyl-3-pyridinyl) -hexahydro-1H-pyrrolizine hydrochloride
7a- (5-Methyl-3-pyridinyl) -hexahydro-1H-pyrrolizine was dissolved (109 mg,
0. 54 mmol) in Et 2 O, and Et 2 O saturated with HCl (g) was added. The solvent was removed and the solid was triturated with Et 2 O and dried to give the title compound as a white powder (112 mg, 87%); mp 153-154 ° C; 1 H NMR (D 2 O, 300 MHz) d 2.12-2.49 (m, 9H), 2.57-2.66 (m, 2H), 3.34-3.43 (m, 2H), 3.79-3.87 (m, 2H), 7.90 (s, 1H ), 8.46 (s, 1H), 8.52 (s, 1H); MS (CI / NH3) m / z: 203 (M + H) +; MS (CI / NH3): m / z 203 (M + H +), 220 (M + NH4 +). Anal. Caled for C13H18N2 »1.4 HCl: C, 61.63; H, 7.72; N, 11.06. Found: C, 61.82; H, 7.89; N, 11.00
EXAMPLE 22 Salt of 7a- (5-bromo-6-fluoro-3-pyridinyl) -hexahydro-1H-pyrrolizine 22a.7a- (5-bromo-6-fluoro-3-pyridinyl) -hexahydro-1 H- hydrochloride pyrrolizine n-BuLi (2.5 M in hexanes, 0.252 ml, 0.63 mmol) was added to di-isopropylamine (0.082 ml, 0.63 mmol) in THF and stirred at room temperature for 10 minutes, then cooled to -78 ° C. 7a- (6-Fluoro-3-pyridinyl) -hexahydro-1H-pyrrolizine (123 mg, 0.60 mmol, from Example 12d) and 1,2-dibromo-1,1,1,2-tetrafluoroethane (0.215 ml, 1.80 mmol). The mixture was slowly warmed to room temperature and stirred overnight. The reaction was quenched with HCi 2 N, and the mixture was washed with Et 2 O. The aqueous layer was basified with 15% NaOH and extracted with methylene chloride. The organic extracts were combined, dried (MgSO4) and concentrated. The residue was subjected to chromatography (silica gel; CHCl3 / MeOH, 99: 1) to give the title compound as an oil (64 mg, 37%). 1 H NMR (CDCl 3, 300 MHz) d 1.59-1.71 (m, 2H), 1.79-2.06 (m, 6H), 2.64-2.72 (m, 2H), 3.12-3.19 (m, 2H), 8.14 (dd, J = 8.8, 2.2 Hz, 1H), 8.19 (dd, J = 2.2, 1.2 Hz, 1H); MS (CI / NH3) m / z: 285/287 (M + H) +.
22b. 7a- (5-Bromo-6-fluoro-3-pyridinyl) -hexahydro-1H-pyrrolizine hydrochloride salt 7a- (5-bromo-6-fluoro-3-pyridinyl) -hexahydro-1H-pyrrolizine was dissolved in Et2O , and Et2O saturated with HCl (g) was added. The solvent was removed, and the solid was triturated with Et 2 O and dried to give the title compound as a white powder (59 mg, 87%): mp 213-215 ° C; 1 H NMR (D 2 O, 300 MHz) d 2.15-2.49 (m, 6H), 2.56-2.65 (m, 2H), 3.34-3.42 (m, 2H), 3.78-3.87 (m, 2H), 8.31 (dd, J = 2.4, 1.0 Hz, 1H), 8.38 (dd, J = 7.8, 2.4 Hz, 1H); MS (CI / NH3) m / z: 285/287 (M + H) +; MS (CI / NH3): m / z 285/287 (M + H +). Anal. Caled for C12H14BrFN2 «HCI: C, 44.81; H, 4.70; N, 8.71. Found: C, 45.04; H, 4.25; N, 8.48.
EXAMPLE 23 Salt of 7a- (5-chloro-6-fluoro-3-pyridinyl) -hexahydro-1H-pyrrolizine hydrochloride
7a- (5-Chloro-6-fluoro-3-pyridinyl) -hexahydro-1 H -pyrrolizine n-BuLi (2.5 M in hexanes, 0.232 mL, 0.58 mmol) was added to di-isopropylamine (0.077 mL, 0.58 mmol) in THF and stirred at room temperature for 15 minutes, then cooled to -78 ° C. 7a- (6-Fluoro-3-pyridinyl) -hexahydro-1H-pyrrolizine (115 mg, 0.56 mmol, from Example 12d) and hexachloroethane (400 mg, 1.7 mmol) were added. The mixture was slowly warmed to room temperature and stirred overnight. The reaction was quenched with 2N HCl, and the mixture was washed with Et2O. The aqueous layer was basified with 15% NaOH and extracted with methylene chloride. The organic extracts were combined, dried (MgSO4) and concentrated. The residue was subjected to chromatography (silica gel; CHCl 3 / MeOH, 99: 1) to give the title compound as an oil (45 mg, 34%): 1 H NMR (CDCl 3, 300 MHz) d 1.60-1.72 (m , 2H), 1.80-2.06 (m, 6H), 2.64-2.72 (m, 2H), 3.14-3.27 (m, 2H), 8.00 (dd, J = 8.8, 2.0 Hz, 1H), 8.15 (dd, J = 2.0, 1.0 Hz, 1H); MS (CI / NH3) m / z: 241 (M + H) \ 7a- (5-Chloro-6-fluoro-3-pyridinyl) -hexahydro-1H-pyrrolizine hydrochloride salt 7a- (5-chloro) -6-fluoro-3-pyridinyl) -hexahydro-1 H-pyrrolizine in Et 2 O, and Et 2 O saturated with HCl (g) was added. The solvent was removed and the solid was triturated with Et 2 O and dried to give the title compound as a white powder (35 mg, 74%): mp 181-183 ° C; 1 H NMR (D 2 O, 300 MHz) d 2.15-2.50 (m, 6H), 2.56-2.65 (m, 2H), 3.34-3.42 (m, 2H), 3.79-3.87 (m, 2H), 8.24-8.29 (m 2H); MS (CI / NH3) m / z: 241 (M + H) +; MS (CI / NH3): m / z 241/243 (M + H) +. Anal. Caled for C12H14CIFN2 »HCl: C, 52.00; H, 5.45; N, 10.11. Found: C, 51.81; H, 5.62; N, 9.84.
Example 24 Salt of 7a- (4-methyl-3-pyridinyl) -hexahydro-1 H-pyrrolizine hydrochloride
24a. 3-amino-4-methylpyridine 2-Chloro-4-methyl-3-nitropyridine (10.2 g, 59.1 mmol, Aldrich) and 10% Pd / C (1.5 g) in MeOH (250 mL) were combined under 4 atmospheres of H2 for 20 hours at room temperature. The reaction mixture was filtered and the filtrate was concentrated. The residue was subjected to chromatography (silica gel; CHCl 3 / MeOH, 95: 5) to give a white solid (6.1 g, 96%): 1 H NMR (CDCl 3, 300 MHz) d 2.17 (s, 3 H), 6.96 ( d, J = 4.8 Hz, 1H), 7.94 (d, J = 4.8 Hz, 1H), 8.02 (s, 1H); MS (CI / NH3) m / z: 109 (M + H) +.
24b. 3-Iodo-4-methylpyridine. 3-Amino-4-methylpyridine (2.0 g, 8.5 mmol) in DME (9.0 ml) was added dropwise to a solution of boron trifluoride diethyl etherate (3.4 ml, 27.7 mmol). ) in DME (35 ml) at -1 7 ° C. After stirring for 1 5 min, t-butyl nitrite (2.6 ml, 22.2 mmol) in DME (37.0 ml) was carefully added to the reaction mixture while maintaining the temperature below -5 ° C. After complete addition, the temperature was allowed to gradually rise to 5 ° C over 1 h. After re-cooling to -1 7 ° C, pentane was added and decanted. The solid was triturated with pentane (2X) and Et2O (2X), then the solvent was removed via positive N2 pressure to give a white solid. The crude diazonium tetrafluoroborate salt was dissolved in acetonitrile (70 ml) and Kl (3.4 g, 20.3 mmol) was added at -10 ° C. The reaction was allowed to warm gradually to room temperature and stirred overnight. A solution of 10% sodium thiosulfate) was carefully added to the reaction mixture, which was then poured onto Et2O and the phases were separated. The organic phase was dried (MgSO4) and concentrated, and the residue was subjected to chromatography (silica gel; EtOAc / hexane, 1: 1 5) to give an amber oil (2.2 mg, 54%): 1 H NMR (CDCl 3 , 300 MHz) d 2.42 (s, 3H), 7.19 (d, J = 4.8 Hz, 1 H), 8.38 (d, J = 4.8 Hz, 1 H), 8.86 (s, 1 H).
24c. 7a- (4-methyl-3-pyridinyl) -hexahydro-1 H -pyrrolizine 3-iodo-4-methylpyridine (330 mg, 3.10 mmol) was dissolved in Et 2 O and cooled to -95 ° C. A solution of t-BuLi (1.7 M in pentane, 4.0 mL, 6.80 mmol) in pentane was added in the form of drops. 1, 2,3,5,6,7-hexahydropyrrolizinium perchlorate (960 mg, 4.60 mmol) was added and the reaction mixture was allowed to warm to -10 ° C with stirring for 2 hours. The cold bath was removed, 2N HCl was added and the phases were separated. The aqueous phase was basified with 15% NaOH and extracted with CH2Cl2 (2X). The CH2Cl2 fractions were combined, dried (MgSO4) and concentrated, and the residue was subjected to chromatography (silica gel; CHCl 3 / MeOH, 99: 1) to give the title compound as an oil (41 mg, 6%): 1 H NMR (CDCl 3, 300 MHz) d 1.54-1.69 (m, 2H), 1.77-1.89 (m, 2H ), 1.93-2.11 (m, 4H), 2.41 (s, 3H), 2.69-2.77 (m, 2H), 3.08-3.15 (m, 2H), 7.02 (d, J = 4.8 Hz, 1H), 8.32 ( d, J = 4.8 Hz, 1H), 9.06 (s, 1H); MS (CI / NH3) m / z: 203 (M + H) +.
24d. 7a- (4-Methyl-3-pyridinyl) -hexahydro-1H-pyrrolizine dihydrochloride salt 7a- (4-Methyl-3-pyridinyl) -hexahydro-1 H -pyrrolizine (37 mg, 0.18 mmol) was dissolved in Et2O , and Et2O saturated with HCl (g) was added. The solvent was removed and the solid was triturated with Et20 and dried to give the title compound as a white solid (26.2 mg, 61%): mp 244-247 ° C; 1 H NMR (D 2 O, 300 MHz) d 2.01-2.16 (m, 2 H), 2.27-2.52 (m, 4 H), 2.65 (s, 3 H), 2.65-2.78 (m, 2 H), 3.45-3.54 (m, 2 H) ), 3.87-3.96 (m, 2H), 7.75 (d, J = 5.6 Hz, 1H), 8.49 (s, 1H), 8.55 (d, J = 5.6 Hz, 1H); MS (CI / NH3) m / z: 203 (M + H) +. Anal. Caled for C 13 H 18 N 2 »2 HCl: C, 56.73; H, 7.32; N, 10.18. Found: C, 56.94; H, 7.24; N, 9.99.
Example 25 7a- (5-phenyl-3-pyridyl-hexahydro-1H-pyrrolizine-25a, 3-bromo-5-phenylpyridine hydrochloride salt) 3,5-Dibromopyridine portions (1.0 g, 4.22 mmol) were combined phenylboronic acid (570 mg, 4.6 mmol) and palladium tetra (triphenylphosphine) (60 mg) in toluene (20 ml) with aqueous sodium carbonate solution (2M, 3.0 ml) and heated to reflux for 6 hours. it was cooled to room temperature, and the solvent was removed The residue was purified by chromatography (silica gel, levigating with ether: hexane 1: 1 0 to give the title compound: MS (CI / NH3) m / z: 234 / 236 (M + H) +, 251/153 (M + NH 4) +; 1 H NMR (CDCl 3, 300 MHz) d 7.21 -8.02 (dd, J = 2.0, 2.0 Hz), 8.65 (d, J = 2.0 Hz), 8.75 (d, J = 2.0 Hz).
25b. 7a- (5-phenyl-3-pyridinyl) -hexahydro-1 H -pyrrolizine 3-Bromo-3-phenylpyridine (200 mg, 0.85 mmol) was dissolved in Et 2 O and cooled to -30 ° C. A solution of t-BuLi 2.5 M (1.1 mL, 1.90 mmol) in pentane was added, and the reaction was stirred for 10 minutes. Add 1, 2,3, 5,6,7-hexahydropyrrolizinium perchlorate (230 mg, 1.30 mmol) and allow the reaction mixture to stir for 30 minutes at -30 ° C, then allow Warm to room temperature and stir for 1 hour. Then 2N HCl was added, the phases were separated and the aqueous phase was basified with 1% NaOH and extracted with CH2Cl2 (2X). The organic phases were combined, dried (MgSO) and concentrated, and the residue was subjected to chromatography (silica gel; CHCl3 / MeOH, 95: 5) to give a clear oil (32.5 mg).
25c. 7a- (5-phenyl-3-pyridinyl) -hexahydro-1H-pyrrolizine hydrochloride salt The compound 7a- (5-phenyl-3-pyridinyl) -hexahydro-1H-pyrrolizine from step 25b was dissolved in ether (5H-pyrrolizine hydrochloride). ml) and Et 2 O saturated with HCl (g). The solvent was removed, and the solid was dried to give the title compound as yellow needles (13.5 mg): mp 217-220 ° C (dea); 1 H NMR (D 2 O, 300 MHz) d 2.17-2.47 (m, 4 H), 2.57-2.73 (m, 4 H), 3.41-3.50 (m, 2 H), 3.87-3.97 (m, 2 H), 7.60-7.68 (m , 3H), 7.75-7.81 (m, 2H), 8.60 (dd, J = 2.0, 2.0 Hz, 1H), 8.87 (d, J = 2.0 Hz, 1H), 9.04 (d, J = 2.0 Hz, 1H); MS (CI / NH3) m / z: 265 (M + H) +. Anal. Caled for C18H20N2.2.0 HCU0.1 H2O: C, 63.76; H, 6.60; H, 8.26. Found: C, 63.62; H, 6.48; N, 8.02.
Claims (8)
1 . A compound that has the formula or a pharmaceutically acceptable salt or prodrug thereof, wherein the group designated A is selected from the group consisting of: (a) wherein R1 is C? -C3-alkyl, as defined below, -CH2-aryl, -CH2-substituted aryl, or -CH2-CH2-substituted aryl, wherein aryl and substituted-aryl are as define later; (b) wherein R1 is as defined above, and R2 is H or dCa-alkyl; (c) wherein R3 is substituted at the 2, 4 or 6 position and is selected from the group consisting of H, d-Cs-alkyl, Br, Cl or F; and R4 is substituted in one of the remaining positions not occupied by R3 and is independently selected from the group consisting of H, C? -C3-alkyl, Br, Cl, F or d-C3-alkyl-0-; or when substituted at position 5, R4 may be further selected from the group consisting of (1) O-R6, wherein R6 is selected from the group consisting of; (a) hydrogen, (b) alkyl of one to six carbon atoms, (c) alkenyl of one to six carbon atoms, (d) alkynyl of one to six carbon atoms, (e) haloalkyl of one to six atoms carbon, (f) hydroxyalkyl of two to six carbon atoms, (h) amino, (i) alkylamino of one to six carbon atoms, (j) dialkylamino, in which the two alkyl groups are independently from one to six carbon atoms, (k) phenyl, (I) naphthyl, (m) biphenyl, (n) furiio, (o) thienyl, (p) pyridinyl, (q) pyrazinyl, (r) pyridazinyl, (s) pyrimidinyl, t) pyrrolyl, (u) pyrazolyl, (v) imidazolyl, (w) indolyl, (x) thiazolyl, (and) oxazoyl, (z) isozasolyl, (aa) thiadiazolyl, (bb) oxadiazolyl, (ce) quinolinyl, ( dd) isoquinolinyl, (ee) aryl-Ci-Ce-alkyl, (ff) heteroaryl-d-Cß-alkyl t (gg) any of groups (i) to (ff) of R 6 above substituted with one or two selected substituents independently of the group consisting of at alkyl of one to six carbon atoms, haloalkyl of one to six carbon atoms, alkoxy of one to six carbon atoms, alkoxyalkyl, in which the alkoxy and alkyl portions are independently from one to six carbon atoms, alkoxyalkoxy, wherein the alkoxy moieties are independently from one to six carbon atoms, halogen, cyano, hydroxy, amino, alkylamino of one to six carbon atoms, carboxyl and alkoxycarbonyl of two to six carbon atoms; (2) -S-R6, wherein R6 is as defined above; (3) -N (R6) (R7), wherein R6 is as defined above and R7 is selected from H or alkyl of 1 to 6 carbon atoms; (4) LR8, wherein L is absent or selected from the group consisting of (a) - (CH2) p-, where p is 1 to 6; (b) - (CH = CH) q-, where q is one or two; (c) -C (O) -; (d) -OC (O) -; (e) -N (R7) -C (O) -, wherein R7 is as defined above; (f) -CH2-CH2-C (O) -; (g) -CH2-O-C (O) -; -CH2-NH-C (O) -; or (h) -C = C-; and wherein -R8 is selected from the group consisting of: (a) hydrogen; (b) alkyl of one to six carbon atoms, (c) alkenyl of one to six carbon atoms, (d) alkynyl of one to six carbon atoms, (e) haloalkyl of one to six carbon atoms, (f) hydroxyalkyl of two to six carbon atoms, (g) alkoxy of one to six carbon atoms (h) amino, (i) alkylamino of one to six carbon atoms, (j) dialkylamino, in which the two alkyl groups are independently from one to six carbon atoms, (k) phenyl, (I) naphthyl, (m) biphenyl, (n) furyl, (o) thienyl, (p) pyridinyl, (q) pyrazinyl, (r) pyridazinyl, (s) pyrimidinyl, (t) pyrrolyl, (u) pyrazolyl, (v) imidazolyl, (w) indolyl, (x) thiazolyl, (y) oxazolyl, (z) isozasolyl, (aa) thiadiazolyl, (bb) oxadiazolyl, (ce) quinolinyl, (dd) -syquinolinyl, and (ee) any of groups (i) to (dd) of R 6 above substituted with one or two substituents independently selected from the group consisting of alkyl of one to six atoms of carbon, haloalkyl of one to six carbon atoms, alkoxy of one to six carbon atoms, alkoxyalkyl, in which the alkoxy and alkyl portions are independently from one to six carbon atoms, alkoxyalkoxy, in which the portions of alkoxy are independently from one to six carbon atoms, halogen, cyano, hydroxy, amino, alkylamino of one to six carbon atoms, carboxyl, and alkoxycarbonyl of two to six carbon atoms; with the requirement that in groups of the type -O-R6, -S-R6, -N (R6) (R7) and L-R8, none of R6, -N (R6) (R7) or L-R8 can contain a nitrogen atom, which is conjugated with a double or triple ligature; (), where R3 is as defined above; (e) where R3 is as defined above; (f) where R3 is as defined above; Y (9) where R5 is H, C? -C3-alkyl, Cl or F.
2. A compound according to claim 1, wherein A is selected from options (a) and (c).
3. A compound according to claim 2, wherein A is selected from option (c).
4. A compound according to claim 1, which is 7a- (3-methyl-5-isoxazolyl) -hexahydro-1 H-pyrrolizine; 7a- (1 H-3-methyl-5-pyrazo I il) -hexahydro-1 H-pyrrolizine; 7a- (3-pyridinyl) -hexahydro-1 H-pyrrolizine; 7a- (3-quinolinyl) -hexahydro-1 H-pyrrolizine; 7a- (6-chloro-3-pyridinyl) -hexahydro-1 H-pyrrolizine; 7a- (2-fluoro-3-pyridinyl) -hexahydro-1 H -pyrrolizine; 7a- (2-chloro-3-pyridinyl) -hexahydro-1 H -pyrrolizine; 7a- (5,6-dichloro-3-pyridinyl) -hexahydro-1 H-pyrrolizine; 7a- (5-pyrimidinyl) -hexahydro-1 H -pyrrolizine; 7a- (2,6-difluoro-3-pyridinyl) -hexahydro-1 H-pyrrolizine; 7a- (2,6-dichloro-3-pyridinyl) -hexahydro-1 H -pyrrolizine; 7a- (6-fluoro-3-pyridinyl) -hexahydro-1 H -pyrrolizine; 7a- (3-ethyl-5-isoxazole i) -hexah id ro-1 H-pyrrolizine; 7a- (3-propyl-5-isoxazolyl) -hexahydro-1 H -pyrrolizine; 7a- (3-benzyl-5-isoxazolyl) -hexahydro-1 H -pyrrolizine; 7a- (5-hydroxy-3-pyridinyl) -hexahydro-1 H -pyrrolizine; 7a- (5-benzyloxy-3-pyridinyl) -hexahydro-1 H -pyrrolizine; 7a- (5-bromo-3-pyridinyl) -hexahydro-1 H-pyrrolizine; 7a- (6-fluoro-5-methyl-3-pyridinyl) -hexahydro-1 H -pyrrolizine; 7a- (6-chloro-5-methyl-3-pyridinyl) -hexahydro-1 H-pyrrolizine; 7a- (6-methyl-3-pyridinyl) -hexahydro-1 H-pyrrolizine; 7a- (5-methyl-3-pyridinium) -hexahydro-1 H -pyrrolizine; 7a- (5-bromo-6-fluoro-3-pyridinyl) -hexahydro-1 H -pyrrolizine; 7a- (5-chloro-6-fluoro-3-pyridinyl) -hexahydro-1 H -pyrrolizine; 7a- (4-methyl-3-pyridinyl) -hexahydro-1 H -pyrrolizine; 7a- (5-phenyl-3-pyridinyl) -hexahydro-1 H -pyrrolizine.
5. A compound according to claim 1, wherein the compound has binding affinity in both a nicotinic alpha-4-beta-2 receptor subtype and a nicotinic alpha-7 receptor subtype.
6. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) in combination with a pharmaceutically acceptable carrier.
7. A method for selectively controlling synaptic transmission in a mammal, comprising administering a therapeutically effective amount of a compound of formula (I) to a patient in need of treatment thereof. A method for ligating a nicotinic alpha-7 receptor subtype, which comprises administering a compound of formula (I) to an in vitro or in vivo screen or to a patient in need or treatment thereof. SUMMARY 7a-substituted hexahydro-1H-pyrrolizine compounds having formula (I), wherein A is a defined heterocyclic moiety, pharmaceutical compositions of these compounds, and the use of said compositions to selectively control synaptic transmission in mammals. (
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08802978 | 1997-02-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA99007626A true MXPA99007626A (en) | 2000-01-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0846114B1 (en) | 3-pyridyloxyalkyl heterocyclic ether compounds useful in controlling chemical synaptic transmission | |
EP1359152B1 (en) | Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands | |
US5629325A (en) | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission | |
CA2285263C (en) | Furopyridine, thienopyridine, pyrrolopyridine and related pyrimidine, pyridazine and triazine compounds useful in controlling chemical synaptic transmission | |
US20030225268A1 (en) | Diazabicyclic CNS active agents | |
WO1994008992A1 (en) | Heterocyclic ether compounds that enhance cognitive function | |
BG107303A (en) | Diazabicyclic central nervous system active agents | |
US5733912A (en) | 7A-heterocycle substituted hexahydro-1H-pyrrolizine compounds useful in controlling chemical synaptic transmission | |
EP0842178B1 (en) | Furopyridine, thienopyridine, pyrrolopyridine and related pyrimidine, pyridazine and triazine compounds useful in controlling chemical synaptic transmission | |
US6437138B1 (en) | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission | |
AU2022325137A1 (en) | Cyanopyridine and cyanopyrimidine bcl6 degraders | |
CA2287223A1 (en) | 2-azabicyclo compounds | |
MXPA99007626A (en) | 7a-HETEROCYCLE-SUBSTITUTED HEXAHYDRO-1H-PYRROLIZINE COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | |
US6656958B2 (en) | Substituted pyridine compounds useful for controlling chemical synaptic transmission | |
WO2024035688A1 (en) | Macrocyclic bcl6 degraders | |
EP1257535B1 (en) | Substituted pyridine compounds useful for controlling chemical synaptic transmission |